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Abstract:  
 
 This study examines the effects of a chronic high-fat diet (HFD) and chronic endurance 
exercise (CEE) upon muscles of varying oxidative (Ox) and glycolytic capacities. We report that 
chronic HFD leads to significantly high levels of blood glucose and insulin concentrations. These 
high concentrations were due to the reduction in the activity of key proteins in the insulin-
signaling (IS) cascade, leading to blunted rates of glycogen synthesis (GSR) and reduced 
glucose-6-phosphate (G6P) content in all muscles fiber types (MFTs) of HF fed rodents. 
Conversely, CEE increased insulin sensitivity, increased GSR and G6P content. Our work has 
shown that hyperlipidemia causes all MFTs to develop insulin resistance regardless of Ox 
capacity. However, it appears that the Ox fibers are more severely affected by insulin resistance 
and that the pathogenesis of insulin resistance is different between muscle fiber types.  
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1. Introduction 
 
The rise of obesity rates worldwide is alarming. By the year 2030, it is estimated that the 
number of obese adults will rise to 1.35 billion and overweight adults will rise to 375 million1. 
Epidemiological studies have indicated that obesity is an important risk factor for heart disease, 
hypertension, and diabetes2. Diabetes alone is projected to rise from 171 million in 2000 to 366 
million by 20303. Diabetes can be categorized into two etiopathogenic categories: type I and type 
II (T2D)4. Type I is developed as a result of an autoimmune pathogenesis occurring in the 
pancreatic islets which leads to complete loss of the β-cell’s ability to secrete insulin4. This form 
of diabetes only accounts for 5-10% of all cases while T2D accounts for 90-95% of cases4. T2D 
patients are able to produce insulin, however, they show a blunted response to insulin action4. 
The reduced or impaired response to insulin observed in T2D subjects is known as ‘insulin 
resistance’5. Obesity has become the most critical factor in the pathogenesis in metabolic 
diseases, which is one reason why obese subjects tend to develop insulin resistance5. The state of 
insulin resistance is characterized by a reduction in insulin-stimulated glucose transport and 
metabolism6. The decrease in glucose transport translates to severe reductions in the ability of 
peripheral tissues, more specifically the muscle, to dispose of glucose and aid glycemic control6.  
Muscle glycogen synthesis is one of the key pathways for glucose disposal, as it accounts for 
up to 75% of the insulin-stimulated whole-body glucose disposal7. This is due to the fact that the 
skeletal compartment makes up a significant part of total body mass (~40% and 30% of total 
body mass in men and women, respectively) and it can store up to 1 to 2% of its weight in 
glycogen8-9. Impairment in the ability of skeletal muscles to uptake glucose and synthesize 
glycogen in response to insulin can markedly reduce the clearance of glucose from the 
circulation and lead to hyperglycemia.  
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Hyperglycemia is avoided via insulin stimulated muscle glucose uptake. Insulin stimulation 
initiates a cascade of intracellular signaling events that lead to translocation of glucose 
transporter 4 (GLUT 4) to the plasma membrane of the myocyte10. Once located at the plasma 
membrane, GLUT 4 facilitates the influx of glucose11. This is concomitantly followed by the 
activation of key enzymes involved in the regulation of glycogen synthesis12. The ability for 
insulin to trigger such intracellular events in the muscle is crucial for proper regulation of 
glycemia. However, it is important to note that the skeletal muscle contains different fiber types, 
each with their own distinct metabolic characteristics.  
One of the principle differences between fiber types is the amount of mitochondrial content.  
This is an important difference as recent research has shown that the obese state can cause 
changes to insulin sensitivity and disrupt the insulin-signaling cascade through a number of 
mechanisms that are directly or indirectly influenced by mitochondrial activity. These include 
increased oxidative stress8, elevated levels of inflammatory cytokines13, and accumulation of 
intramyocellular lipid intermediates14. Among these mechanisms, it is the accumulation of 
intramyocellular lipids intermediates specifically diacylglycerol (DAG) and ceramides that have 
received a lot of attention14. This theory is supported by observations that the increased DAG 
content in muscle cells, which are oversupplied with lipids, causes the impairment of the 
subsequent intracellular signaling15. Therefore, it is anticipated that conditions that reduce DAG 
content help prevent the development of insulin resistance and disturbances to glucose 
metabolism. In this context, it is not known how muscles that express a mitochondria rich muscle 
fiber type cope with diet-induced obesity, and whether a fiber type, which expresses more 
mitochondria, is more suited to dealing with diet-induced obesity over a fiber type that expresses 
less. 
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2. Literature Review 
2.1 Muscle Fiber Type  
 
 Systemic plasma glucose concentrations are tightly regulated through a complex system 
of glucose uptake and delivery16; this careful regulation is vital in order to avoid the adverse 
effects of hypo- and hyperglycemia17. In the postprandial state, plasma glucose elevations are 
balanced by triggering an insulin response that stimulates cells to uptake and utilize glucose22-23. 
This regulation of insulin-stimulated glucose disposal occurs through the interaction of a number 
of tissues, including the liver, brain, skeletal muscle, small intestine, pancreas and adipose 
tissue18. After the brain, skeletal muscle exerts the largest influence over insulin-stimulated 
glucose disposal18.  
Skeletal muscle consists of varying fiber types each with distinct physiological 
characteristics19. Based on histochemical staining and enzymatic analysis, muscle fibers have 
been categorized into three groups: type I (slow twitch oxidative muscles), type IIa (fast twitch 
oxidative and glycolytic muscles) and type IIb (fast twitch glycolytic muscles)20. An example of 
a muscle rich in type I fibers is the soleus muscle23. This particular muscle is comprised mainly 
of intermediate and slow twitch motor units and its fibers are rich in mitochondria23. Type I 
fibers have greater insulin binding capacity, have increased insulin receptor kinase activity and 
autophosphorylation capacity in comparison to fast twitch type II glycolytic fibers21,22. Type I 
fibers are red and fatigue resistant due to an abundance of mitochondria and myoglobin. These 
fibers undergo oxidative metabolism which is used to provide a stable and sustainable supply of 
ATP23. Conversely, type II fibers are less oxidative due to fewer mitochondria and myoglobin 
content23. Type II fibers can be further subcategorized into type IIa and type IIb fibers. Type IIa 
contains both oxidative and glycolytic enzymatic properties and as a result, have a slightly 
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greater rate of fatigue than type I fibers23. Finally, type IIb fibers essentially rely on glycolytic 
metabolism and have the lowest amount of mitochondria23. Type IIb only provides a short burst 
of ATP making these fibers more prone to fatigue23. 
 In the context of diabetes, studies have demonstrated a link between fiber type and 
insulin resistance19-20. Patients with T2D have a higher number of glycolytic fibers, particularly 
type IIb, a feature which has been linked to insulin resistance26-27. Type I fibers, on the other 
hand, are correlated with insulin responsiveness and maximal oxygen uptake28. However, under 
diabetic conditions, type I fibers display reduced content of insulin receptors, insulin receptor 
substrate-1, and glucose transporter 4 (GLUT4) proteins28. 
2.2 Mechanisms of Muscle Glucose Uptake !
 It has been established that improper functioning or reduced content of GLUT4 is a key 
factor in the pathogenesis of insulin resistance29. The GLUT4 is a member of a category of 
proteins known as glucose transporters (GLUTs)24. GLUT4 is present in insulin-responsive 
tissues such as the skeletal and cardiac muscles, and is crucial to the regulation of systemic 
glycemia because it facilities the diffusion of glucose from circulation into the muscle cells30-31. 
During this process, elevated glycemia stimulates the release of insulin30. This hormone then 
binds to its receptors on muscle cells and leads to a cascade of intracellular signaling events that 
culminate with the translocation of GLUT4-containing vesicles from the perinuclear region to 
the plasma membrane12,32. GLUT4 fuses with the plasma membrane and promotes the transport 
of circulating glucose into the cell (Figure 1.0). In fact, experiments using 3-O-methyl glucose 
have shown that insulin stimulation causes an 8.6-fold increase in glucose uptake33. This 
significant fold increase in insulin-stimulated glucose uptake is accompanied by an 8-fold 
increase in the presence of GLUT4 at the plasma membrane of muscle cells33. 
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2.3 Intramuscular Glucose Metabolism 
 
Once inside the muscle cell, glucose can be metabolized through various pathways34. 
However, experiments utilizing euglycemic-hyperinsulinemic clamps have shown that 
intramuscular glucose is primarily disposed of via glycogen synthesis35. Thus, glycogen 
synthesis is the primary pathway of glucose disposal during the postprandial state. Inside the cell, 
glucose is actively phosphorylated to form glucose-6-phosphate (G6P)36. G6P can either be 
catabolized through glycolysis or stored as glycogen37. Subjects with impaired glucose tolerance 
display a severe reduction in glycogen synthesis and, to a lesser extent, glycolysis38. 
Furthermore, under hyperinsulinemic and hyperglycemic condition muscle glycogen synthesis 
becomes the predominant means of glucose disposal37-38. Hyperglycemic-hyperinsulinemic 
clamps along with NMR analysis, have also shown that the rate of muscle glycogen synthesis 
decreased by 60% in diabetic subjects in comparison to controls41. Moreover, it was found that 
glycogen synthesis accounts for 90% of non-oxidative glucose disposal and 70% of whole-body 
glucose metabolism41.  
Since muscle glycogen synthesis is the principal means of insulin-stimulated glucose 
disposal researchers have attempted to define the proteins that are considered as the potential rate 
limiting elements of skeletal muscle glycogen synthesis. The three key proteins thought to be 
involved are glycogen synthase (GS), GLUT4 and hexokinase II (HKII) 42-43. HK II is the 
enzyme responsible for the phosphorylation of glucose that enters the myocyte via GLUT4, 
whereas GS is the terminal enzyme in muscle glycogen synthesis that actively converts uridine 
5′-diphosphate-glucose (UDP-Glu) into glycogen (Figure 1.0)44. It has been determined that the 
primary rate-limiting protein of muscle glycogen synthesis is GLUT4. This was based on 
observations that subjects who suffered from lipid-induced insulin resistance had a decrease in 
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both intramuscular glucose and G6P content45. This provided evidence that glucose transport was 
impaired in these subjects as less glucose was entering the cell, thus less was being actively 
converted into G6P46. 
2.4 Mechanism of Intramuscular Insulin Signaling !
The signaling mechanisms by which insulin stimulates glucose uptake and metabolism 
are a complex and involve the interaction of many enzymes47. Insulin is a peptide hormone that 
is produced by the β-cells of the pancreas and functions as a potent regulator of whole body 
glycemia48. Once secreted, insulin circulates in the bloodstream and binds to its receptors present 
on the plasma membrane of myocytes47.  
The insulin receptor (IR) consists of two extracellular α-subunits and two transmembrane 
β-subunits that are linked by disulfide bonds49. Upon insulin binding to its receptor, the α-subunit 
induces tyrosine autophosphorylation of the β-subunit and vice versa50. This leads to 
phosphorylation of the insulin receptor substrates (IRS)50. IRS proteins are a critical node of 
insulin-signaling, particularly the IRS-1 and IRS-2 isoforms. In fact, it has been demonstrated 
that IRS-1 knockout mice presented with skeletal muscle insulin resistance, while IRS-2 
knockout mice display hepatic insulin resistance46-47. Furthermore, a decreased expression of IRS 
proteins has been associated with obesity52. 
Phosphorylation of the tyrosine residues induces a conformational change in IRS 
proteins53. This conformational change generates a “docking site” that allows for proteins 
containing the src-homology-2 (SH2) domains to interact with and facilitate further signal 
transduction53. SH2 domains are present in p85α which is a regulatory subunit of 
phosphatidylinositol-3-OH kinase (PI3K)53. When p85α activity is upregulated via insulin 
stimulation, it binds with a catalytic subunit known as p110 to form active PI3K54. Activation of 
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PI3K causes the phosphorylation and intracellular accumulation of phosphatidylinositol (3,4,5)-
trisphosphate (PIP3)55. PIP3 is the vital secondary messenger in the initiation of the downstream 
signaling enzyme phosphoinositide-dependent kinase-1 (PDK1)56. 
PDK1 then stimulates the phosphorylation of protein kinase B (Akt), a serine/threonine 
kinase that exists in 3 isoforms (Akt 1, 2 and 3).52 Akt is known as a critical signaling factor in 
the regulation of cellular metabolism, growth, and survival52. Studies in humans have shown that 
impairment of the phosphorylation and activation of Akt as a contributing factor to skeletal 
muscle insulin resistance52. Thus, PI3K phosphorylation of threonine 308 and serine 473 residues 
of Akt are critical to the signal transduction, and this phosphorylation leads to the downstream 
phosphorylation of glycogen synthase kinase-3 (GSK-3)57,58.  
GSK-3 exists in 2 isoforms: α and β, and unlike most other kinases, it is constitutively 
active in cells59. Its activity is inhibited by extracellular factors, such as insulin or epidermal 
growth factor58. However, when active, GSK-3 indirectly regulates the activity of glycogen 
synthase (GS) by reducing the activity of protein phosphatase-1 (PP1)60. PP1 is essential in the 
activation of GS, as under basal conditions GS exists in its inactive phosphorylated form, P-GS. 
When insulin stimulation occurs, PP1 is activated as a result of GSK-3’s phosphorylation, 
causing it to be deactivated59. PP1 activation will cause the dephosphorylation of sites 3a, 3b, 3c 
and 4 of GS on serine residues 640, 644, 648 and 652, respectively.61 Dephosphorylation of GS 
will activate this enzyme and promote glycogen synthesis. Any interruption of insulin action will 
decrease GS activity and this is detrimental to glycogen synthesis as GS is the terminal enzyme 
of this pathway60. The activity of GS is not only regulated by covalent action via insulin 
stimulation, but it is also controlled through allosteric regulation by G6P62.  
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Figure 1: Schematic of glucose uptake and glycogen synthesis via insulin stimulation. 
Insulin binds to its receptors (1) and triggers autophosphorylation of IRS-1 protein at the tyrosine 
residue (2). Tyrosine phosphorylation of IRS-1 leads to the activation of PI-3K (3), which, in 
turn, leads to PIP3 accumulation (4) and activation of PDK1 (5). The latter promotes 
phosphorylation of AKT (6). Phosphorylated AKT then promotes phosphorylation/deactivation 
of GSK-3 (7). Additionally, AKT also aids in the signaling involved in translocation GLUT4 to 
the plasma membrane (8) GSK-3 phosphorylation causes GS to be dephosphorylated and hence 
activated. (9). Once fused to the membrane, GLUT4 facilitates the entry of glucose that is then 
phosphorylated by hexokinase II (HK) producing glucose 6 phosphate (G6P) (10). (11), G6P 
undergoes subsequent enzyme action by phosphoglucomutase (PGM) leading to the production 
of glucose 1-phosphate (G1P) (12). G1P subjected to action ubiquitin-proteasome pathway 
(UPP) leading to the production of uridine diphosphate glucose (UDP-Glu) (13). UDP-Glu is 
finally converted into glycogen via the active GS. Adapted from Lawrence and Roach42. !
GS has nine different amino acid residue sites and it can undergo multi-site 
phosphorylation63. The activation of this enzyme requires the phosphorylation of more than one 
of its amino acid residues61,63. It is not just a number of different sites that require 
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phosphorylation but phosphate groups must be added in a particular order and this is described as 
ordered hierarchical phosphorylation63. Hierarchical phosphorylation requires a number of 
regulatory phosphorylation sites; each unit contains a primary phosphorylation site and a 
secondary site (Figure 2.0)63.  For example, the deactivation of GS via GSK-3 only occurs when 
GS has been previously phosphorylated by casein kinase II44. In this case, casein kinase II is a 
primary site kinase which phosphorylates site 5, while GSK-3 is the secondary site kinase which 
phosphorylates sites 3a, 3b, 3c and 4 leading to the deactivation of GS44. Hierarchical 
phosphorylation has been exemplified in vivo and this has demonstrated that the phosphorylation 
of sites 3a, 3b, 3c and 4 occurs to a greater extent once casein kinase II has phosphorylated of 
site 564.  
3  4  5 
a b c
3  4  5 
CK II 
3  4  5 3  4  5 
3  4  5 
1) 2) 
3) 4) 
5) 
Dephosphorylated Glycogen Synthase 
Phosphorylated Glycogen Synthase 
GSK-3 
GSK-3 
UDP-
Glu 
GS Glycogen 
GSK-3 
GSK-3 
GSK-3 GSK-3 CK II 
CK II CK II 
CK II 
GS a b c
a b ca b c
a b c
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Figure 2: Schematic representation of the ordered hierarchical phosphorylation on sites 3, 
4 and 5 of GS, via GSK-3 and casein kinase II (CKII), 1) Dephosphorylated sites 3, 4 and 5 of 
GS protein 2) After muscle glycogen synthesis is complete, inactivation of GS is initiated via CK 
II phosphorylation of site 5, followed by subsequent phosphorylation of site 4 by a GSK-3. 3) 
Proceeding site 4, site 3c is phosphorylated 4) Followed by site 3b 5). Finally, site 3a is 
phosphorylated completing the deactivation of GS. Adapted from Roach63. 
 
In addition to undergoing hierarchical phosphorylation, GS is present as two distinctive 
isoforms: the active (I) and inactive (D) G6P-independent forms65. The major structural 
difference between I and D isoforms is the presence of a covalently bonded phosphate group on 
the D isoform64. These isoforms are interchangeable through reversible covalent modifications, 
whereby the D can change to the I isoform or vice versa66.  Leloir et al. were the first to show 
that G6P can activate GS and further research has established that G6P is an allosteric regulator 
of GS62. Allosteric regulation is achieved by G6P binding to an amino acid residue found on the 
structure of GS44. Upon binding to GS, G6P causes the rearrangement of specific amino acid 
residues, which in turn causes conformational changes of GS (Figure 3)44.  This structural change 
of GS renders the enzyme more vulnerable to dephosphorylation via phosphatases 1 and 2A 
(Figure 3)67.  
The allosteric activation of GS is a more potent form of activation than covalent 
activation65. This was made evident by a study in mice expressing a mutant GS enzyme65. The 
mutated protein would not be activated by G6P, but would still be able to undergo 
dephosphorylation upon insulin stimulation of the myocyte65. Mice expressing the G6P-
insenstive GS enzyme exhibited an approximate 80% reduction of insulin-stimulated muscle 
glycogen synthesis65. This study demonstrates allosteric activation as the primary pathway for 
GS activation during insulin-stimulated glycogen synthesis65.    
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Figure 3: Schematic representation of glucose-6-phosphate allosteric and covalent 
regulation, that lead to the development of either I or D isoform of glycogen synthase. 1) GS 
present in its D, inactive, form 2) GS is allosterically activated when G6P binds to GS, and 
stimulates a conformational change 3) the binding of G6P over-rides the phosphate action upon 
GS, thus activating the enzyme. Additionally, the change in shape leaves the phosphate groups 
more vulnerable to protein phosphatases 4) Phosphatases remove the phosphate groups, thus 
activating GS 5) GS is now active with or without the G6P 6) After no further muscle glycogen 
synthesis is required GS is covalently inactivated by the addition of the phosphate groups via 
casein kinase II and GSK-3. Adapted from Villar-Palasi and Guinovart68. !!!!!!!
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2.5 Insulin resistance and its effects on muscle  !
 Muscle glycogen synthesis is one of the main processes affected by T2D. The 
fundamental concern in type 2 diabetic patients is that they often display high concentrations of 
insulin in the circulation since they are resistant to the action of this hormone4. Similarly, obese 
subjects tend to develop insulin resistance which suggests a link between obesity and T2D5. The 
state of insulin resistance is characterized by a reduction in insulin-stimulated glucose transport 
and metabolism69. The decrease in glucose transport leads to a subjugation in the ability of 
peripheral tissues, more specifically the skeletal muscle, to aid in systemic glycemic control70. 
This leads to hyperinsulinemia since the pancreas attempts to compensate for this by increasing 
insulin secretion71. 
Over the years varying mechanisms have been discovered that provide a greater 
understanding as to why insulin resistance develops in the muscle.  Mechanisms involving the 
production of inflammatory cytokines71, increased concentrations of glucocorticoids72, increased 
reactive oxygen species (ROS) production,8 and intramyocellular accumulation of lipid 
intermediates73 have been identified as inducers of insulin resistance. The common feature 
shared by all of these mechanisms is that each condition can result of impairment of normal 
mitochondrial functioning from the excessive intake of a lipid rich diet, which is typical of 
obesity. Thus, it is essential to comprehend how diet-induced obesity (DIO) affects skeletal 
muscle glucose metabolism. 
2.5.1 Inflammatory Cytokines 
 
 It is becoming increasingly understood that the adipose tissue it not just a site of storage 
but a metabolically active tissue, that is capable of producing biologically active substances 
known as adipokines74. With consumption of a high-fat diet, there is a significant expansion of 
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the adipose tissue that triggers the release of adipokines. Specific adipokines such as tumor-
necrosis factor α (TNF-α) and interlukin-6 (IL-6) have been linked to the development of insulin 
resistance in muscle75-76,66-67.  
TNF-α is a pleiotropic cytokine with the ability to induce apoptosis, cell proliferation, 
and stimulate the production of inflammatory molecules79. TNF-α is mainly produced by 
macrophages, particularly those that have infiltrated inflamed, obese adipose tissue66-67. It can 
also be produced by skeletal muscle79. The deletion of TNF-α and its receptors in mice makes 
these animals less susceptible to developing insulin resistance80. TNF-α increases serine 
phosphorylation of IRS-1 via the mitogen-activated protein kinase pathway; which interrupts the 
insulin signaling cascade and prevents further activation of downstream targets80. 
IL-6 has proven to be quite controversial, as some studies report that IL-6 has the ability 
to increase insulin sensitivity and glucose transport in muscle81, whereas others have shown that 
muscle-derived IL-6 can have adverse effects on glucose metabolism82. Acute in vivo treatment 
of mice with IL-6 reduces PI3K activity and insulin-stimulated glucose uptake82. This has been 
attributed to the promotion of serine phosphorylation of IRS proteins as opposed to tyrosine, thus 
impairing the ability of insulin to increase PI3K activity82.  
2.5.2 Reactive Oxygen Species (ROS)    !
Similar to inflammatory agents, hyperlipidemia can cause an increase in the production 
of ROS. The link between obesity and ROS is demonstrated by research indicating that increases 
in FFA concentrations causes oxidative stress as a result of mitochondrial uncoupling83. 
Oxidative stress is defined as a state where ROS concentrations overwhelm the endogenous 
antioxidant capacities of a system84. When ROS concentrations reach these heights, an inverse 
relationship with glycemic control is developed 85. ROS are formed when electrons escape the 
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electron transport chain and react with oxygen to form a reactive molecule that contains oxygen 
and a charged species known as superoxide (O2·−)86. Superoxide is converted by manganese 
superoxide dismutase (SOD) to hydrogen peroxide (H2O2)87. H2O2 can then be reduced to water 
when found in the mitochondria and reduced to water and oxygen when found outside the 
mitochondria87. Skeletal muscle can generate superoxides and if there is inadequate removal, 
then O2·− and H2O2 can cause a redox imbalances in the myocyte that lead to the activation of 
stress-sensitive intracellular signaling pathways88. Activation of these pathways increases the 
activity nuclear factor kappa-light-chain-enhancer (NF-κB) and PKC, factors that are able to 
cause insulin resistance88. NF-κB is a transcription factor that regulates the expression of a 
number of genes, some of these genes include the pro-inflammatory cytokines: TNF-α and IL-
688. PKC is a kinase that can be activated by lipid metabolites and interrupts in the insulin 
signaling cascade88 (this is discussed in greater detail later in this paper).  It is hypothesized that 
if mitochondria can be manipulated to increase the activity of SOD to reduce O2·− accumulation, 
then perhaps oxidative stress may be avoided89. Lark et al. (2015) attempted to prove this 
hypothesis by breeding mice that overexpress SOD with mice that have enhanced H2O2 
scavenging89. They concluded that mice that solely overexpress SOD and the mice that retain the 
SOD overexpressing gene and the enhanced H2O2 scavenging gene are not protected from diet-
induced insulin resistance89. Rather it seems that the mice who only have enhanced H2O2 
scavenging gene can avoid diet-induced insulin resistance and thus drugs that can mitigate this 
pathway will benefit the treatment of insulin resistance more so than those that target O2·−89. 
However, the increase of FFA uptake is not the only means by which ROS concentrations 
can increase. Obesity can cause increases in ROS production. The excess adipose tissue that 
develops in the obese state is able to produce and secrete into circulation, the peptide hormone 
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angiotensin II (ANG II)90. Transgenic rats who overexpress angiotensin II (ANG II) exhibit an 
increase of ROS which thus induces insulin resistance of the skeletal muscle91-92. Under these 
conditions, ROS have the capacity to affect various insulin signaling pathways such as PI3K 
activity70. Additionally, when ANG II increases ROS production in skeletal muscle, it leads to 
the impairment of the tyrosine phosphorylation of IRS protein, AKT activation and glucose 
transport91.  
2.5.3 Glucocorticoids 
  
 Glucocorticoids are a class of steroid hormones which bind to glucocorticoid receptors: 
and unlike other hormones (such as insulin) its receptors are found in the cytoplasm93. 
Glucocorticoids are a subcategory of corticosteroids and cortisol is a corticosteroid, which is 
produced by the adrenal cortex. Cortisol behaves as a glucocorticoid in that it binds to the 
glucocorticoid receptor, thus the term glucocorticoids is used to describe cortisol that has 
glucocorticoid activity72. One of the main functions of glucocorticoid is to maintain blood 
glucose levels during times of physiological stress94. Glucocorticoids inhibit glucose uptake by 
the muscle and even promote gluconeogenesis95. As such, there is a clear link between the 
excessive action of this hormone and insulin resistance94.  
It has been shown that the production of glucocorticoids is increased in the insulin 
resistant and obese states96. The detrimental effects of glucocorticoids’ are likely due to their 
ability to alter glucose metabolism non-genomically72. After chronic dexamethasone (an 
exogenous glucocorticoid) treatment, insulin-stimulated phosphorylation of AKT was 
decreased72. The decreased phosphorylation of AKT could be attributed to a decrease of IRS-1 
tyrosine phosphorylation and IRS protein expression97. This effect was paralleled by decreased 
glucose uptake and disposal in skeletal muscle93. Glucocorticoids do not alter GLUT4 content, 
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but rather the action of GLUT4 is decreased in dexamethasone-treated Sol tissue93. It is 
important to note that these effects are not solely caused by glucocorticoids that derive from the 
adrenal gland since they can also be produced in the muscle via 11β-hydroxysteroid 
dehydrogenase type 1 (11β-HSD1)98, which is an enzyme that actively converts cortisone into 
glucocorticoids98. An elevation of 11β-HSD1 content/activity is observed in obese insulin-
resistant humans even when plasma glucocorticoid concentrations are normal94. According to 
Morton et al. (2001), 11β-HSD1 knockout mice are more glucose tolerant and display an 
improved lipid profile when placed under stress or induced to obesity99. However, the exact 
pathways by which these improvements occur are still unclear.  
2.5.4 Lipid-mediated Insulin Resistance 
  
The notion of lipids potentiating insulin resistance is! exemplified by Santomauro et al. 
(1999) who demonstrated that overnight reduction of free fatty acids from ~600 to ~300 µmol/l 
normalized insulin sensitivity in obese non-diabetic patients100. The insulin-sensitizing effect of 
lowering circulating fatty acid levels can be linked to the ‘glucose-fatty acid cycle’ proposed by 
Philip Randle101.  This cycle describes the interplay between glucose and fatty acid fuel selection 
that is present in mammalian tissues101. Randle et al. (1964) theorized that increases in fat uptake 
would cause an increase in fatty acid oxidation, which would inhibit pyruvate dehydrogenase, 
increase cytoplasmic citrate concentrations and inhibit phosphofructokinase activity102. This 
would lead to an accumulation of G6P and inhibition of hexokinase II activity (figure 4.0, A).  
However, these findings contrast more recent work by Roden et al. (1996) and Dresner et 
al. (1999) who found that there is a decrease of intramyocellular G6P in humans with increased 
plasma fatty acid concentrations45,103. This research concluded that fatty acids caused skeletal 
muscle insulin resistance as a result of inhibition of glucose transport, instead of inhibiting 
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pyruvate dehydrogenase activity104 (figure 4.0, B). These findings along with more current 
research brought forth a different theory, one that suggests that the impairment of glucose 
transport occurs as a result of a accumulation of toxic lipid intermediates, such as Diacylglycerol 
(DAG) as opposed to the shift in substrate usage that is proposed by the Randle cycle105,106. This 
is considered the most popular hypothesis concerning the development of skeletal muscle insulin 
resistance14. (Figure 4.0, B).  
DAG is a relatively simple lipid molecule comprising of a glycerol molecule linked 
through ester bonds to two fatty acids in positions 1 and 2109. Furthermore, DAG is a well-known 
precursor of IMTG synthesis and it makes up part of the cell membrane and is a second 
messenger signaling lipid109. In the context of skeletal muscle insulin resistance, DAG is a well-
known allosteric activator of protein kinase C (PKC) specifically PKC- θ15. PKC has both 
genomic and non-genomic effects upon the myocyte. The non-genomic effects concern the 
phosphorylation of serine residues of IRS1/2, which prevents insulin-stimulated IRS tyrosine 
phosphorylation15. This causes impairment of the early stages of the insulin-signaling cascade15. 
The genomic effects of PKC relate to increasing the activity of NF-κB 105-106. 
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Figure 4: Schematic representation of (A) Randle theory for the development of insulin 
resistance and (B) Schematic representation of DAG mediated insulin resistance. (A) 
Displaying the Randle cycle’s approach to the development of diet-induced insulin resistance: 
Glucose is usually entering the cell and subject to oxidation or is stored as glycogen. However, 
when there is an abundance of fat in the diet Fatty acids (FA) are actively entering the myocyte 
via cluster of differentiation 36 (CD36). Once inside the myocyte FAs are converted into 
intramuscular triglycerides (IMTGs), these triglycerides enter the mitochondria via carnitine 
palmitoyltransferase I (CPT1) thus β-oxidation (β=ox) rates are increased to help combat this 
influx of LCFA. This results in a significantly higher production of acetyl-CoA, which inhibits 
pyruvate dehydrogenase (PDH) activity and increases citrate concentrations in the mitochondria. 
The accumulation of citrate in the mitochondria causes leakage into the cytoplasm. The accretion 
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of citrate in the cytoplasm not only creates malonyl-CoA but also inhibits hexokinase II (HKII) 
and phosphofructokinase (PFK). The inhibition of these enzymes prevents glucose oxidation 
from taking place and causes an accumulation of G6P in the cell. However, more recent work 
has lead to an alternative hypothesis. (B), This hypothesis states that increased fat intake would 
cause the accumulation of lipid intermediates in the cytoplasm. Primarily diacylglycerol (DAG), 
this lipid will indirectly interrupt the insulin-signaling cascade and lead to reduced activity of 
GLUT4 amongst other things. The result is that glucose remains in the circulation without being 
stored or oxidized.  
2.6 Exercise and Insulin Resistance   
 
 A common and well-documented approach to the reversal and prevention of the effects of 
diet-induced insulin resistance is exercise110-111. Exercise is considered a more powerful means 
of increasing insulin sensitivity than drug interventions. Studies have shown that exercise 
increases insulin sensitivity significantly more than Metformin112 or Troglitazone113 in humans, 
with the additional improvements in cardiovascular and respiratory performance114. In general, 
physical activity levels are lower in those with insulin resistance and pre-diabetes than healthy 
individuals115. The Diabetes Prevention Program showed that exercise reduced the incidence of 
T2D by 58% in individuals who were at significant risk for the development of the disease116. 
Based on the data from healthy subjects, an acute bout of aerobic/endurance exercise of at least 
60% VO2 max for 60-90 minutes is required to stimulate significant improvements in insulin 
sensitivity117. Aerobic training is not the only means by which metabolic profile can be 
improved; resistance training is a valid alternative platform118. Resistance training improves 
GLUT4 protein content and causes hypertrophy of both type I and type II fibers120-121. Yet, the 
overall consensus seems to favor aerobic exercise as the primary form of physical activity. This 
in part may be due to its ability to produce a more significant anti-inflammatory effect as oppose 
to resistance training121. 
There is significant evidence that moderate to high-intensity aerobic training can improve 
muscle insulin sensitivity122. Chibalin et al. (1999) have shown the mechanistic benefits of 
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exercise by assessing the activity of GLUT 4 and key upstream proteins involved in the insulin-
signaling cascade123. In Chibalin’s study, Wistar rats were exercised for one day and five days, 
each day for six hours123. Sixteen hours after the last exercise bout, the epitrochlearis muscle was 
isolated and GLUT4 content and signaling proteins were assessed123. Exercise increased GLUT4 
content 2-fold after a one day bout and 4-fold after a five day bout of exercise123. Insulin-
stimulated tyrosine phosphorylation of IRS-1 and PI-3K activity were markedly increased after 
five days123. IRS-2 expression and IRS-2 associated PI-3K activity increased after one day of 
exercise123. Finally, insulin-stimulated serine/threonine phosphorylation of AKT increased 2.3-
fold after five days of exercise123. Furthermore, in a different study by Jensen et al. (2012) 
exercise was shown to stimulate downstream targets of AKT124. Jensen et al. performed a study 
on lean, obese and T2D human subjects undergoing an acute bout of endurance exercise at 70% 
VO2 max124. It was found that GS serine residues were dephosphorylated regardless of 
inactivation of the AKT downstream target GSK-3124.  Additionally, irrespective of whether the 
subject was lean, obese or type 2 diabetic, exercise caused an increase of the affinity of GS for 
UDP-glucose124.  
Exercise not only improves glucose metabolism, but also stimulates glucose uptake. 
Exercise-mediated glucose uptake is independent of insulin and is activated via muscle 
contractions37. When muscle contractions occur, adenosine 5’-triphosphate (ATP) is broken 
down into adenosine diphosphate (ADP)37. ADP is then further metabolized giving rise to 
adenosine monophosphate (AMP). The latter binds to the catalytic site of 5' adenosine 
monophosphate-activated protein kinase (AMPK)37 causing it to undergo a conformational 
change and activation37. Activated AMPK will promote the phosphorylation of Akt substrate of 
160 kDa (AS160) a known mediator of GLUT4 translocation125. Once phosphorylated AS160, 
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indirectly promotes GLUT4 translocation thus increasing glucose uptake37. Increased glucose 
uptake stimulates HKII activity, which increases G6P content. The augmented concentrations of 
G6P can stimulate allosteric activation of the terminal enzyme in glycogen synthesis, GS.  
The effects of exercise go beyond the insulin-signaling cascade and even affect 
mitochondrial content and functioning126. Physical training improves oxidative capacity in vivo 
this is mostly likely due to increased mitochondrial content and/or increased functionality per 
mitochondrion126.  Increased oxidative capacity and mitochondrial function would also provide a 
reason as to why in the context of lipid-mediated insulin resistance exercise leads to a decrease in 
intramyocellular DAG content and improves insulin sensitivity127. The reduction of intracellular 
DAG concentration has been linked to less PKC-θ activation, which shifts back to normal 
tyrosine phosphorylation of IRS-1 protein, allowing for proper insulin signaling to occur127. 
Exercise and inflammatory cytokines 
IL-6 
Much like DAG, IL-6 is considered a harmful agent in the context of diet-induced insulin 
resistance. This was initially hypothesized due to TNF-α stimulating the production of IL-6128. 
However, in a more recent study in which hyperinsulinaemic–euglycaemic clamp was performed 
in T2D and control patients, it was demonstrated that no relationship existed between insulin 
sensitivity and IL-6129. Part of the controversy surrounding the effects IL-6 results from its 
increased presence during exercise130. In fact, plasma IL-6 levels can increase 100-fold during 
exercise131. Additionally, muscle contractions can cause the increased production of IL-6 
independent from the production of TNF- α132. Highlighting that muscular IL-6 has a role to play 
in metabolism rather than just inflammation132. It was first thought that the severe increase in IL-
6 was a result of an immune response from the muscle in an attempt to address any local damage 
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developed over the course of exercise133. More recently, it has been shown that during exercise 
IL-6 has more of a metabolic than inflammatory role149-151. This notion is supported by 
enhancement of intramuscular IL-6 mRNA expression134 and protein release135 when muscle 
glycogen stores are low136. Further evidence supporting this hypothesis is provided by a study 
demonstrating glucose infusion during exercise reduced plasma IL-6 levels131.  
TNF-alpha 
When IL-6 concentrations increase as a result of exercise, it has been shown that this 
increase helps down-regulate TNF-α concentrations137. TNF-α concentrations can be normalized 
in mice that overexpress the TNF-α gene through a single bout of exercise138. Additionally, 
Balducci et al. (2009) determined that subjects undergoing a bi-weekly endurance-training 
program consisting of 60 min sessions at 70-80% of VO2 max for 12 months exhibited a 
significant decrease in circulating TNF-α levels and improvement in insulin sensitivity139.  
ROS 
Hey-Mogensen et al. (2010) have shown that 10 weeks of exercise training program that 
consisted of stationary cycling for 20-35min, 4-5 times per week at 65% VO2 was able to cause 
significantly less skeletal muscle ROS production in obese control subjects compared to obese 
T2D subjects126.  On the other hand, The generation of ROS from non-mitochondrial sources has 
proven to be important in relation to healthy insulin signaling140. The enigmatic role of ROS is 
linked to the degree and duration of the ROS that is produced83. In other words, the transient 
increases in ROS concentrations in the myocyte can help improve insulin sensitivity, but 
sustained concentrations as seen in hyperlipidemia will cause harmful effects126.  
Glucocorticoids 
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 The effect of exercise upon elevated glucocorticoids within an animal model is still 
undergoing research. The most recent work by Beaudry et al. (2015) has shown that exercised 
animals (voluntary exercise) with exogenously elevated glucocorticoids still present with 
hyperglycemia under fasted conditions. However, exercised animals glycemic values were 
significantly lower in comparison to the sedentary animals with elevated glucocorticoids141. It 
should be noted that in both of these groups, a high fat diet was administered. Therefore, high fat 
fed exercised animals with elevated glucocorticoids exhibited an improved, but not normalized 
metabolic profile compared to their sedentary counterparts141. 
Despite the uncertainty surrounding the precise effect of exercise upon certain 
mechanistic factors of diet-induced obesity, exercise has shown to be a very effective tool in 
reversing the detrimental effects of HF-diet-induced insulin resistance.  
2.7 Underlying questions of skeletal muscle insulin resistance 
 
What is the unifying theory in HF induced skeletal muscle insulin resistance? 
 
Almost all the theories that attempt to explain the development of HF induced skeletal 
muscle insulin resistance (except glucocorticoids) share a similar premise, chronic HF feeding 
can negatively affect the mitochondria (Figure 5A). It is hypothesized that the mitochondria are 
becoming overwhelmed by the excessive lipid uptake. This can result in the production of excess 
O2·−, and inadequate removal of O2·− stimulates the activation of inflammatory transcription 
factors, that leads to the production of TNF-α and IL-68. The mitochondria are also central to the 
Randle cycle theory, as it is suggested that chronic HF feeding causes an increase in citrate 
output from the mitochondria which prevents glucose utilization in the muscle142. Finally, there 
is the most popular theory describing the pathogenesis of skeletal muscle insulin resistance143. 
The theory, which involves lipid uptake surpassing mitochondria oxidation rates leading to toxic 
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lipid intermediate build up143. This theory is currently considered the predominating cause of 
skeletal muscle insulin resistance, that is why the focus of our study will be on this pathway144. 
With all these different pathways in mind it is clear that mitochondria content must be taken into 
consideration when discussing skeletal muscle insulin resistance. 
With respect to the muscle, the amount of mitochondria is related to the muscle fiber type 
composition in the muscle. Of the two major muscle fiber types in skeletal muscle, type I fibers 
contain the most mitochondria. As a result these fibers are able to oxidize fats more easily, while 
type II fibers contain less mitochondria, thus the oxidation of fats is not as efficient. This crucial 
difference between muscle fibers is not normally considered with studies concerning lipid 
induced skeletal muscle insulin resistance research. We agree with comments by Dr. ZengKui 
Guo, who suggests that when a study is conducted on muscle of mixed fiber type, extrapolating 
the findings of a study to apply to all muscle fiber types may not be the most accurate 
approach145. To gather an even deeper understanding of the pathogenesis of skeletal muscle 
insulin resistance, the discussion must be broken down into fiber type specific manner (figure 
5B). As it is clear from previous work that type I fibers are significantly more insulin sensitive 
than type II fibers. Type II fibers are more heavily expressed in T2D patients than type I fibers. 
This is all that is in known about fiber type specific insulin resistance thus in our study we would 
like to focus upon one of the most well researched pathways that lead to skeletal muscle insulin 
resistance but observe its pathogenesis between a number of muscles expressing predominantly 
one muscle fiber type (figure 7). Additionally, we want to include an exercise component to our 
study that allows us to observe how chronic endurance exercise affected fiber type specific 
insulin resistance (figure 7).  
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Therefore, the main hypothesis of this study was that muscles rich in mitochondria would 
less susceptible to suffering from toxic lipid intermediate build up when compared to muscles 
with lower amounts of mitochondria (figure 6). The rationale behind this hypothesis was that 
fiber types with more mitochondria would be less likely to be overwhelmed with lipids due to a 
greater capacity to oxidize lipids.  In order to test this hypothesis, we used an animal model 
exposed to lipid oversupply (high-fat diet) either under sedentary or chronically endurance-
trained conditions. 
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Figure 5: (A) A schematic briefly highlighting the key research topics concerning the pathogenesis of skeletal muscle insulin 
resistance and how they are normally researched. (B) A similar schematic of key insulin resistance research topics but 
adjusted to address topics in a fiber type specific manner, the focus of our study is highlighted in green.
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Figure 6: A schematic illustrating the approach to our study, we will be discussing insulin resistance in a more fiber type 
specific way rather than generalizing findings to all muscle fiber types. Our hypothesis is also highlighted in this schematic: type I 
fibers are more likely in maintaining their insulin sensitivity due to their abundance of mitochondria, while type II fibers will be more 
susceptible to mitochondrial dysfunction and metabolic inflexibility due to a significantly lower amount of mitochondria thus leading 
to insulin resistance. 
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Figure 7: A schematic displaying the rich body of research present in the field of skeletal muscle insulin resistance. Our work 
(highlighted in purple) is critical in better understanding how the pathogenesis of skeletal muscle insulin resistance maybe different in 
different muscle fiber types.  
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3. Objectives and Hypotheses !
The hypotheses that this study tested were:  
a) That highly oxidative muscles are less prone to developing insulin resistance under 
conditions of lipid oversupply than highly glycolytic ones.  
b) Endurance exercise will stimulate greater insulin sensitivity in oxidative muscles and 
consequently provide greater protection from the build-up of toxic lipid intermediates.    
These hypotheses were tested through the following objectives:  
1. Using an animal model to observe how chronic high-fat feeding along with physical 
inactivity or activity affects insulin sensitivity. This model will separate rodents into 4 
conditions: Sedentary SC (SED SC), sedentary high fat (SED HF), exercise SC (EX SC) 
and exercise HF (EX HF). 
2. Measuring fasted circulating glucose and insulin levels to determine if our model was 
successful in developing systemic insulin resistance.  
3. Harvesting muscles that favor specific muscle fiber types after the 8 weeks to assess 
glycogen synthesis rates and glycogen content to comprehend if the ability of the 
glycolytic muscles to synthesize and store glycogen was more severely affected than 
oxidative muscles.  
4. Western blots analysis probing for key mechanistic proteins involved in the insulin-
signaling cascade, to observe whether oxidative fibers are less affected by the disruptions 
in the insulin-signaling cascade caused by chronic HF feeding.  
5. Assessing G6P content between muscle fiber types in each condition, which will help 
determine if any of the three muscles G6P production was differently affected than others. 
! 32!
Studies have shown that training induced GLUT 4 content increase mainly in type I 
fibers146, thus more G6P content should be expected in trained oxidative fibers. 
6. Measuring intramuscular palmitate oxidation to establish the oxidative capacities of each 
muscle. Additionally, we will observe how chronic HF feeding affects the fatty acid 
oxidation rates in muscles of varying oxidative capacities.  
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4. Materials and Methods 
4.1 Reagents 
 
 Rat Triacylglycerol quantification kit and glucose 6 phosphate assay kit was purchased 
from Abcam (Toronto, Canada). Specific antibodies against Akt, P-Akt (Thr 308 and Ser 473), 
GSK-3β, P-GSK-3α/β (Ser 21 of GSK-3α and Ser 9 of GSK-3β), GS, P-GS (Ser 641, site 3a) 
were from Massachusetts, USA. [1-14C]palmitic acid and D-[U-14C]glucose was obtained from 
GE Healthcare Radiochemicals (Quebec, Canada). Human insulin (Humulin R) was purchased 
from Eli Lilly Inc. (Toronto, Ontario, Canada).   
4.2 Animals 
 
  Male albino rats Wistar strain (Charles River Laboratories, Montreal, Quebec, Canada) 
weighing 45-55 g were maintained in a 12-hour light (07:00-19:00) and 12-hour dark cycle 
(19:00-07:00) at 22°C with ad libitum access to water and standard chow (SC) diet. The rats 
were allowed to acclimatize for 1 week upon their arrival and then they were fed a SC diet until 
they achieved a body mass of ~250g. Animals were individually housed so that body weight 
(BW) and food intake could be monitored on a daily basis. Subsequently, the diet and/or exercise 
interventions begun and BW and food intake were continuously measured on a daily basis 
throughout the study. Animals were randomly assigned to one of the following groups: 
Sedentary SC (SED SC), sedentary high fat (SED HF), exercise SC (EX SC) and exercise HF 
(EX HF). The SC diet consisted of 60.0 % carbohydrate, 13.0 % fat, and 27.0 % protein (3.43 
kcal/g). The HF diet consisted of 20.0% carbohydrate, 60.0% fat, and 20.0% protein (5.24 
kcal/g). The York University Animal Care Ethics Committee has approved all experimental 
procedures.  
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4.3 Exercise Selection 
 
  Following acclimatization, the rats underwent an exercise selection protocol to identify 
animals that are not willing to run. This selection protocol was done on three separate occasions. 
It began with a 5 min warm up at a speed of 10 m/min with 5% inclination on the treadmill. The 
speed was then increased by 2 m/min every 2 min for 30 min. Animals that were capable of 
running beyond 20 m/min for 20 min on all three occasions were placed in an exercise group. 
Those that were unable to fulfill these criteria were placed in the sedentary group.  
Figure 8.0: Exercise selection protocol 
Stage Speed (m/min) Incline (%) Duration 
Warm up 10 0 5 
1 12 5 2 
2 14 10 2 
3 16 10 2 
4 18 10 2 
5 20 10 2 
6 22 10 2 
7 24 10 2 
8 26 10 2 
9 28 10 2 
10 30 10 5 
4.4 Peak VO2 tests 
 
 Peak VO2  tests were conducted at weeks 0, 2, 4, and 6 of the study in order to adjust the 
intensity of exercise as the endurance capacity of the animals improved. Peak VO2 tests in rats 
were conducted using the Comprehensive Laboratory Animal Monitoring System (CLAMS) 
through an exercise protocol of incremental workloads. Prior to initiating the peak VO2 tests, 
resting VO2 was measured. Subsequently, a 5 min warm-up period consisting of running at 10 
m/min with no inclination began. Once the warm-up period was over, the inclination and speed 
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of the treadmill were increased to 12 m/min and 5%, respectively, for the next 2 min. 
Subsequently, the treadmill inclination was raised to 10% and maintained at that level throughout 
the test, while the speed was increased by 2 m/min every 2 min. The animals were required to 
run until exhaustion, which was characterized by the animals remaining on the shocking pad for 
5 consecutive seconds, by reaching a plateau in VO2 despite increased speed, and/or by reaching 
a RER value of 1 or greater. 
4.5 Endurance Training protocol  
 
 Rats in the endurance training groups were exposed to treadmill running at 70 – 85% of 
peak VO2, 1h/day, 5 days/week for 8 weeks. The intensity range of 70-85% of peak VO2 was 
chosen based on the recommendations by the American College of Sports Medicine (ACSM) to 
improve cardiovascular fitness and promote health benefits in humans147. Peak VO2 tests were 
conducted bi-weekly in order to adjust the exercise intensity as the animals improved their 
aerobic capacity with training. Additionally, to maintain equal conditions among all groups, the 
SED  animals were placed on the treadmill for 1h/day at a speed of 2 m/min. 
4.6 Glucose Tolerance Test (GTT) !
After acclimatizing, at week 0 a GTT was done to gather baseline measurements of 
glycemic control. After 8 weeks of diet and exercise interventions, the animals were fasted 
overnight and baseline (time 0) blood glucose measurements were taken by saphenous vein 
bleeding. Subsequently, each animal received an intraperitoneal (IP) injection of glucose (2g/kg 
of BW) prepared in a 30% glucose solution in physiological saline. Plasma glucose was 
determined after 15, 30, 60, 90, and 120 min by the glucose oxidase method using the OneTouch 
UltraMini blood glucose monitoring system from LifeScan Canada Ltd (BC, Canada). Blood was 
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also collected after 15, 30, 60, 90, and 120 min for the determination of serum insulin 
concentrations. After collection, blood was centrifuged for 10 min at 13,000 rpm (4°C) and 
plasma was then extracted and stored at -80°C.   
4.7 Circulating Insulin !
After a 14-hr fast, blood samples were collected from the saphenous vein at week 0, 3, & 
6 for analysis of circulating insulin concentrations. Samples were immediately centrifuged @ 
13,000 rpm for 10 min (4°C). Plasma was extracted and stored at - 80°C. Plasma was assayed 
using a commercially available ELISA from EMD Millipore (Cat # EZRMI-13K).!
4.8 Muscle isolation and incubation  
 
If animals were exercised, 24 hours of rest was given before they were anesthetized with 
a single i.p. injection of ketamine/xylazine (90 mg and 10 mg/100g B.W., respectively). 
Subsequently, the soleus (Sol), extensor digitorium longus (EDL), and epitrochlearis (Epit) 
muscles were quickly extracted. These muscles were chosen because of their wide range of 
reported fiber-type distributions with distinct mitochondrial contents and oxidative capacities. 
The percentages of type I, type IIa and type IIb in Sol, EDL and Epit muscles are 84/16/0, 
3/57/40, and 15/20/65, respectively148-149. Three sets of muscle strips (18 – 22 mg) were prepared 
from each muscle and mounted onto thin stainless steel wire clips in order to maintain optimal 
resting length. The muscle strips were immediately placed in plastic scintillation vials containing 
2 ml of pre-gassed [30 min with O2:CO2-95:5% (vol/vol)] Krebs-Ringer bicarbonate (KRB) 
buffer with added 4% fat-free BSA and 6 mM glucose. These vials were sealed with rubber 
stoppers and gasification was continued for the entire one hour pre-incubation period. Following 
the pre-incubation period, one set of muscles was transferred to vials containing 2 ml of the same 
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KRB buffer plus D-[U-14C] glucose (0.2 µCi/ml) and incubated under continuous gasification for 
one additional hour either in the absence (basal) or presence of insulin (100 nM) for glycogen 
synthesis determination. Another set of muscles were transferred to vials containing 2 ml of the 
KRB buffer and incubated under continuous gasification for one additional hour either in the 
absence or presence of insulin (100nM) for the purposes of assessing insulin signaling. 
4.9 Assays 
 
 After muscle isolation and extraction, tissues were immediately snap-frozen in liquid 
nitrogen and stored in -80oC until subsequent analysis. 100mg of Sol, EDL and Epit basal tissue 
were weighed and homogenized, triacylglycerol and G6P content of homogenates were 
determined using their commercially available assay kits from Abcam. 
4.10 Measurement of glycogen synthesis and content in isolated muscles  
 
Glycogen synthesis was assessed by measuring the incorporation of D-[U-14C]glucose 
into glycogen as previously described.150 Briefly, immediately after incubation, muscle strips 
were quickly washed in ice-cold PBS, blotted on filter paper, frozen (N2), and digested in 0.5 ml 
of 1mol/l KOH at 70°C for 1 hour. Of the digested muscle solution, aliquots were taken for the 
determination of glycogen content (100ul) and glycogen synthesis (400ul). To each of the 
glycogen synthesis aliquots, 100ul of carrier glycogen, 80ul of saturated Na2SO4 and 1.2 ml of 
Ethanol was added. Solutions were vortexed and left to precipitate overnight at -20°C. The tubes 
were then centrifuged and the remaining pellets re-suspended in 0.5 ml of water and its 
radioactivity determined using a scintillation counter. 
Glycogen content was measured using 100 µl of the KOH digested sample. 10% (v/v) of 
acetic acid 17M, 500 µl of acetate buffer (4.8 pH) with amyloglucosidase (0.5 mg/ml) was added 
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and the resulting solution was left to incubate at room temperature overnight. On the following 
day, the solution was neutralized with 1/16 (v/v) of NaOH (5N). Then, 1 ml of ATP-TRA buffer 
was added to each sample and then vortexed. Finally, 1 ml of the solution was placed in a cuvette 
and counted on the spectrophotometer at 340 nm. 
4.11 Measurement of palmitate oxidation in isolated muscles  
 
 Palmitate oxidation was measured by assessing the production of 14CO2 from [1-14C] 
palmitic acid. The flasks where muscle strips were incubated and contained 2 ml of KRB buffer 
and 0.2 mM of cold palmitic acid previously complexed with fatty acid-free BSA and [1-14C] 
palmitic acid (0.2 µCi/ml). The muscles were incubated under continuous gasification for one 
hour in vials in which a centered isolated well held a loosely folded piece of filter paper 
moistened with 0.2 ml of 2-phenylethylamine/methanol (1:1, vol/vol). Following the one hour 
incubation period, the muscles were rapidly removed and the media acidified with 0.2 ml of 
H2SO4 (5N). The flasks were immediately re-sealed and incubated for an additional one hour to 
collect the 14CO2 released. Subsequently, the filter papers were carefully removed and transferred 
to scintillation vials containing 10 ml of scintillation fluid for radioactivity counting. 
4.12 Western blotting analysis of content and phosphorylation of Akt, GSK3, and GS   
 
 Incubated muscle strips were homogenized in a buffer containing 25 mmol/l Tris-HCl and 
25 mmol/l NaCl (pH 7.4), 1 mmol/l MgCl2, 2.7 mmol/l KCl, 1% Triton-X, and protease and 
phosphatase inhibitors (0.5 mmol/l Na3VO4, 1 mmol/l NaF, 1 mmol/l leupeptin, 1 mmol/l 
pepstatin, and 20 mmol/l PMSF). Muscle homogenates were centrifuged and the supernatant was 
collected.  An aliquot was used to measure protein content by the Bradford method. Samples 
were diluted 1:1 (vol/vol) with 2 x Laemmli sample buffer, heated to 95° C for 5 min, and 
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subjected to SDS-PAGE. All primary antibodies were used in a dilution of 1:1,000. GAPDH and 
β-actin were used as loading controls. Samples were run with antibodies for Total AKT, P-AKT 
(473 and 308), Total GSK3, P-GSK3α and β, GS, and P-GS. The blots were scanned and density 
was quantified using ImageJ software from National Institutes of Health (Maryland, USA). 
4.13 Statistical analysis !
All data was analyzed using a two-way ANOVA with Bonferroni multiple comparisons 
post-hoc tests indicated in the figure legends. The level of significance was set at p< 0.05. All 
statistical analysis was done using Graph Pad Prism 5. We evaluated the fold changes from basal 
glycogen synthesis rates to insulin-stimulated glycogen synthesis rates. These calculations of 
glycogen synthesis rates fold changes between the basal and insulin-stimulated condition were 
performed to provide insight on how insulin sensitive the muscles were. To evaluate this 
sensitivity we divided a rat’s insulin-stimulated glycogen synthesis rate by the same rat’s basal 
glycogen synthesis rate. We did this for all of our rats and then tabulated their means, standard 
deviations and SEMs. Means were then analyzed using a two-way ANOVA with Bonferroni 
multiple comparisons post-hoc tests and the level of significance was set at p< 0.05. !!!!!!!!!!!!
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5. Results 
5.1 Glucose tolerance test (GTT) !
With the exception of time 0, glycemia of the SED HF animals was greater than all other 
conditions at all time points (figure 6A). In fact, glycemia was (which was expressed as area 
under the curve (AUC)) of SED HF rats was 1.29-, 1.61- and 1.19-fold higher than SED SC, EX 
SC, and EX HF groups, respectively (figure 6B). Exercise attenuated this effect, as glycemia of 
the EX HF group was significantly lower than SED HF rats. Additionally, EX HF rats GTT 
response was similar to SED SC condition. SC EX showed the lowest levels of glycemia, 
eliciting values for glycemia that were 1.26-, 1.63- and 1.35-fold lower than SED SC, SED HF, 
and EX HF, respectively. These results indicate exercise can prevent HF-diet-induced insulin 
resistance. 
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Figure 9: Time-course of plasma glucose during a GTT after an overnight fast. AUC = Area 
under the curve, was calculated for each condition followed by a two-way ANOVA followed by 
a Bonferroni post-hoc test. n=14. (B): *p< 0.001 vs. EX SC and p< 0.01 vs. SED HF. § p< 0.05 
vs. SED SC and p< 0.001 vs. EX HF vs. SED HF and # p< 0.001 vs SED SC !!!!
 !
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5.2 Effects of HF diet and exercise on systemic insulin concentrations !
 Fasting plasma insulin concentrations were not different among any of the four 
conditions at week 0. However, by week 3 SED HF insulin concentrations were 1.79-, 2.87- and 
1.96-fold greater than SED SC, EX SC, and EX HF, respectively. This significant difference 
continued during week 6, as SED HF insulin concentrations were 1.96-, 2.46- and 2.03-fold 
greater than SED SC, EX SC, and EX HF, respectively. Intriguingly, EX prevented high 
concentrations of insulin in the EX HF group at both weeks 3 and 6. 
 
 
Figure 10: Measurements of fasting plasma insulin. Blood samples were taken from overnight 
fasted rats to quantify circulating insulin concentrations in SED SC, EX SC, SED HF, & EX HF 
rats. Data are presented as mean ± SEM. Two-way ANOVA followed by a Bonferroni post-test. 
n=6. *p< 0.05 vs. Sed SC; #p< 0.05 vs. Sed HF.  !!!!!!!
!
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5.3 Glycogen synthesis in oxidative and glycolytic muscles  !
Sol (figure 8A), EDL (figure 8B) and Epit (figure 8C) muscles from SED SC rats elicited 
3.39-, 1.75- and 1.97-fold increases in glycogen synthesis in response to insulin, respectively. No 
significant changes were present under basal conditions between SED SC and SED HF 
conditions. 
 Under basal conditions EX SC muscles exhibit a 4.81-, 2.72- and 5.49-fold increase in 
glycogen synthesis in comparison to the SED SC muscles of Sol (figure 8A), EDL (figure 8B) 
and Epit (figure 8C), respectively. Similarly, under basal conditions EX HF muscles showed a 
4.98-, 2.66- and 3.97-fold increase in basal glycogen synthesis rates in Sol (figure 8A), EDL 
(figure 8B) and Epit muscles (figure 8C), when compared to the SED SC condition. Similar 
differences were observed between both EX conditions and the SED HF conditions. Sol (figure 
8A), EDL (figure 8B) and Epit (figure 8C) of EX SC rats, presented a 4.33-, 5.02- and 5.86-fold 
increase in basal glycogen synthesis rates in comparison to SED HF muscles, respectively. 
Finally, muscle from EX HF rats showed a 4.20-, 4.86- and 4.72-fold increase in basal glycogen 
synthesis rates of Sol (figure 8A), EDL (figure 8B) and Epit (figure 8C) in comparison to SED 
HF muscles, respectively. 
 Insulin stimulation of EX muscles caused significant increases in glycogen synthesis 
rates, as EX SC insulin-stimulated glycogen synthesis rates increased by 1.68-, 1.82- and 1.35-
fold in Sol (figure 8A), EDL (figure 8B) and Epit (figure 8C), respectively when compared to 
basal EX SC condition. Furthermore, similar increases in glycogen synthesis rates are were 
found in insulin stimulated EX HF muscles, the Sol (figure 8A), EDL (figure 8B) and Epit 
(figure 8C) respectively, showed a 2.18-, 1.31- and 1.60-fold increase, respectively, when 
compared to basal EX HF condition.  
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 Differences in fold changes from basal glycogen synthesis rates to insulin-stimulated 
glycogen synthesis of each muscle were measured (Figure 8.1). SED SC Sol fold changes were 
significantly greater than all other conditions (p< 0.001). Additionally, EX HF Sol muscle 
exhibited greater fold changes than SED HF Sol, SED HF EDL, SED HF Epit, EX HF EDL and 
EX SC Epit (p< 0.001). To conclude, it seems that the Sol muscle is the most profoundly 
affected muscle in HF induced insulin resistance, as the decrease in the fold changes of glycogen 
synthesis from the SED SC Sol muscle to the SED HF Sol muscle is the largest.  EX HF Sol 
muscle EX seems to prevent insulin sensitivity from declining to similar levels as the SED HF 
group.  
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Figure 11: Glycogen synthesis rates in Sol (A), EDL (B) and Epit (C) of SED SC), EX SC, 
SED HF and EX HF rats. Data are presented as mean ± SEM. Two-way ANOVA followed by 
a Bonferroni post-test. n=3-6.  
$ p< 0.05 vs. all other conditions. 
* p< 0.001 vs. SED SC basal and insulin, vs. SED HF basal and insulin. p< 0.05 vs. EX SC 
basal and vs. EX HF basal.  
# p< 0.01 vs. SED SC basal, vs. SED HF basal and insulin.  
Ψ p< 0.001 vs. SED HF basal p< 0.01 vs. SED SC basal, vs. SED HF basal and insulin.  
Φ p< 0.05 vs. all other conditions.  
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Figure 11.2: Glycogen synthesis fold change differences among oxidative and glycolytic 
muscles. Data are presented as mean ± SEM. Two-way ANOVA followed by a Bonferroni post-
test. n=3-8. * p< 0.001 vs all other conditions. # p< 0.001 vs SED HF Sol, SED HF EDL, SED 
HF Epit, EX HF EDL and EX SC Epit. !
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5.4 Western blotting analysis of content and phosphorylation of Akt, GSK3, and GS: 
Sedentary animals: 
  ! AKT phosphorylation was undetected under basal conditions. However, phosphorylation 
of AKT at serine 473 and threonine 308 was significantly higher in insulin-stimulated Sol, EDL 
and Epit muscles of the SC animals in comparison to HF animals (Figure 9 A-C). AKT 
phosphorylation was significantly reduced in the Sol, EDL and Epit (Figure 9 A-C) muscles of 
HF rats when compared to SC counterparts. Sol, EDL and Epit muscle from SC animals 
displayed a robust phosphorylation of GSK-3 in both alpha (α) and beta (β) isoforms, upon 
exposure to insulin in SC animals. In contrast, insulin-stimulated phosphorylation of GSK-3 α 
and β in all three muscles from HF-fed rats was almost undetected (Figure 9 D-F). Finally, 
insulin caused a marked dephosphorylation of GS in Sol, EDL and Epit muscles from SC rats 
(Figure 9.1 A-C). Muscles from HF rats displayed blunted dephosphorylation of GS (Figure 9.1 
A, B & C). These findings clearly show that insulin signaling is defective in skeletal muscles of 
rats fed a HF diet, which is consistent with the reduction in insulin-stimulated glycogen synthesis 
in oxidative and glycolytic muscles of these animals. !!!
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Figure 12.0: Densitometry and Western Blot - HF feeding inhibits insulin-mediated 
phosphorylation of AKT and GSK3 in skeletal muscles. Representative blots for P-AKT 
Thr308, P-AKT Ser473, P-GSK-3α, and P-GSK-3β under basal (Bas) and insulin-stimulated 
(Ins) conditions in the Sol (A and D), EDL (B and E), and Epit (C and F) muscles. Two-way 
ANOVA followed by a Bonferroni post-hoc test. n=4. Data are presented as mean ± SEM.* p< 
0.05 vs. all other conditions.  
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Figure 12.1: Densitometry and Western Blot - HF feeding inhibits insulin-mediated 
dephosphorylation of GS in skeletal muscles. Representative blots for P-GS under basal (Bas) 
and insulin (Ins)-stimulated conditions in the Sol, (A), EDL (B), and Epit (C) muscles. Two-way 
ANOVA followed by a Bonferroni post-hoc test. n=4. Data are presented as mean ± SEM. * p< 
0.05 vs. all other conditions,  
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5.5 Glucose-6-phosphate content in glycolytic and oxidative muscles !
Significantly lower levels of intracellular G6P were observed in the EDL of both SED SC 
and SED HF groups in comparison to the EX SC and EX HF conditions (figure 10B). The EDL 
of EX SC presented a 4.79-fold increase of intramuscular G6P in comparison to SED SC 
conditions (figure 10B). Additionally, EX SC showed a 12.6-fold increase of intramuscular G6P 
content in comparison to the SED HF group (figure 10B). The EX HF muscles showed a 4.55- 
and 12.4-fold increase of intramuscular G6P content in comparison to the SED SC and SED HF 
conditions, respectively (figure 10B).  An analogous trend is present in the Epit data, as EX SC 
animals demonstrated a 2.77- and 7.07-fold increase in comparison to the SED SC and SED HF 
groups, respectively (figure 10C). Additionally, EX HF Epit muscles presented a 2.09- and 5.30-
fold increase in G6P content compared to the SED SC and SED HF rats, respectively (figure 
10C). Lower concentrations were found in the Sol of both SED SC and SED HF rats but the 
differences compared to the EX condition were not statistically significant (figure 10A). !!!
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Figure 13: Concentration of G6P in the Sol (A), EDL (B) and Epit (C) after the 8-week 
protocol. All tissues are expressed as nmol of G6P per milligram of wet tissue (mg of wet 
tissue). Data are presented as mean ± SEM. Two-way ANOVA followed by a Bonferroni post-
hoc test. n=3-5. # p< 0.001 vs. SED HF and SED SC. $ p< 0.001 vs. SED HF and SED SC.  
p< 0.05 vs. SED HF. * p< 0.05 vs. SED SC, and p< 0.01 vs. SED HF  !!!!!!!!!!!!
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5.6 Palmitate oxidation in glycolytic and oxidative muscles !
As expected, HF-feeding increased the rates of palmitate oxidation by 1.58-, 1.75- and 
1.6-fold in Sol, EDL, and Epit muscles, respectively, when compared to SC rats (figure 11). 
However, the rate of palmitate oxidation was highest in Sol, the most oxidative muscle, followed 
by EDL, and Epit tissues from SC-fed rats (figure 11). SED HF muscles have the greatest rates 
of palmitate oxidation (figure 11.1 A) among all the conditions tested. In the Sol SED HF 
muscles show a 2.41-, 1.90- and 2.03-fold increase in oxidation rates in comparison to SED SC, 
EX SC, and EX HF, respectively. Similarly, in the EDL (figure 11.1 B), SED HF muscles exhibit 
increases of 2.42-, 2.3- and 1.78-fold of oxidation rats in comparison to SED SC, EX SC and EX 
HF, respectively. Finally, SED HF Epit (figure 11.1 C) fatty acid oxidation rates were 1.79-, 
1.53- and 1.38-fold higher than SED SC, EX SC, and EX HF conditions, respectively.  
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Figure 14: The effects of high-fat (HF) diet on palmitate oxidation in oxidative and 
glycolytic muscles. Strips of Sol, EDL, and Epit muscles from SC and HF-fed rats were assayed 
for 14CO2 production from 14C-palmitic acid at week 8 of the study. Data are presented as mean ± 
SEM. Two-way ANOVA followed by a Bonferroni post-test. n=6  * p< 0.05 vs. EDL and Epit 
SC; # p< 0.05 vs. Sol SC; $ p< 0.05 vs. SC.  
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Figure 14.1: Measurement of Palmitate Oxidation of Sol (A), EDL (B) and Epit (C) muscle 
SED SC, EX SC, SED HF and EX HF rats. Data are presented as mean ± SEM. Two-way 
ANOVA followed by a Bonferroni post-test. n=5-7. (A) * p< 0.001 vs SED SC and EX HF, p< 
0.01 vs EX SC. (B) * p< 0.001 vs all other conditions. (C) * p< 0.01 vs SED SC and EX SC. 
 
 
 !!!!!!!!
! 55!
6.0 Discussion !
In this study we provide novel evidence that, Sol, EDL, and Epit muscles of SED HF rats 
develop insulin resistance despite major differences in oxidative capacities of each muscle. All 
three muscles displayed decreased G6P content; reduction in the activity of key mechanistic 
proteins involved in insulin signaling and finally decreased rates of glycogen synthesis. 
Furthermore, our study is the first study to suggest that type I fibers may be more profoundly 
affected by HF-induced skeletal muscle insulin resistance than type II fibers. 
Successful development of systemic insulin resistance 
In our study we showed that SED HF rats displayed a significantly higher concentration 
of both circulating blood glucose and insulin. This provides proof that our model was successful 
in developing diet induced insulin resistance. As the muscle plays one of the largest roles in 
insulin-stimulated glucose disposal, we attribute the hyperglycemia and hyperinsulinemia in 
these rats to the impairment of muscle glucose uptake18.  
Exercise can prevent the development of impaired glucose tolerance  
 
GTT data showed that the EX HF muscles displayed similar glycemic control to SED SC 
muscles. Similarly, fasting insulin data revealed that insulin concentrations were alike between 
the SED SC and EX HF conditions at week 3 and 6. The similar blood glucose and insulin 
concentrations of these two groups are noteworthy as even though a HF diet was fed to the EX 
HF group, this condition still maintained its’ insulin sensitivity and glucose tolerance to the same 
degree as the control group. The ability of the EX HF group to do this can be accredited to the 
adaptive characteristics of exercise37. Characteristics such as exercise-mediated glucose uptake 
and the ability of chronic endurance training to cause a shift in fiber type expression in the 
muscle37,151. Suggesting that exercise simulated increased expression of insulin sensitive type I 
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fibers in the EX muscles, along with exercise-mediated glucose uptake promoting glucose uptake 
and preventing the development of hyperinsulinemia152. The shift to the more insulin sensitive 
type I fibers and the increased glucose uptake in the exercise condition would also explain why 
EX SC condition displayed the lowest levels of blood glucose at all time points.  
HF feeding decreases G6P content in all SED HF muscles 
 
Exercise-mediated glucose uptake and shift in muscle fiber type could also rationalize 
why greater G6P content was found in the EDL and Epit EX conditions in comparison to their 
SED counterparts. Conversely, we found no significant differences in the measurement of G6P 
concentrations among any of the conditions of the Sol muscle. However, when the significant 
increases of G6P in the EX EDL and EX Epit are considered then it was unusual for there to be 
an absence of an increase of G6P content in EX Sol tissue. We concluded that the reason why a 
similar pattern was not found in this muscle is that there was an experimental issue during the 
G6P assay for this muscle.  
The higher concentrations of G6P in the EX EDL and Epit could be a result exercise 
stimulating the increase of GLUT4 translocation37. It is reported that GLUT4 translocation is the 
rate limiting step in non-oxidative glucose disposal, thus increased glucose uptake due to 
exercise will stimulate HKII activity which readily converts glucose to G6P45. Our conclusions 
concerning the increased G6P content in EX muscles is in agreement with other studies, which 
have shown that chronic endurance exercise will increase GLUT4 translocation153. Interestingly, 
the EX SC Epit muscle presented with the highest levels of G6P content, this is a finding that is 
in contrast to other research which indicates, that exercise mediated increases in GLUT 4 content 
are greater in type I fibers than type II146. Furthermore, other work has shown that a greater 
! 57!
percentage of HK II is present in type I fibers than type II, thus it is unclear why the muscle with 
the highest type II fiber percentage had the highest levels of G6P content154. 
All muscles, regardless of fiber type, had key mechanistic proteins of insulin signaling affected  
 
A potential argument for the decrease of intramuscular G6P and the development of 
insulin resistance in all of the SED HF muscles is that HF-feeding diminished GLUT4 protein 
content155. However, insulin resistant subjects have shown to have equal amounts of GLUT4 
content as controls153. A more apt explanation for the lower amounts of G6P in the SED HF 
condition is that SED HF muscles were unable to stimulate glucose uptake. This could have been 
due to the lipid-rich diet causing indirect disruptions to the insulin-signaling cascade, which 
would prevent the translocation of GLUT4. In fact, our Western blot analysis showed that Sol, 
EDL, and Epit muscles from SED-HF rats presented with reduced insulin-stimulated 
phosphorylation of Akt and phosphorylation/deactivation of GSK-3α/β. Moreover, insulin-
induced dephosphorylation/activation of GS was clearly impaired in all three muscles from SED 
HF rats. Although many studies have shown the importance of maintaining the phosphorylation 
of AKT and GSK isoforms and the dephosphorylation of GS, the phosphorylation of the tyrosine 
residue of IRS-1 is one of the initial steps and without its’ phosphorylation the signal is 
arrested50,12. Many studies describing the mechanistic effects of lipid-induced insulin resistance 
indicate that the tyrosine residue of IRS-1 is not phosphorylated, but it is rather the serine residue 
of IRS-1 that undergoes phosphorylation which prevents any further downstream signaling15,156. 
It is plausible that serine phosphorylation took place in our SED HF muscles because we 
observed the blunted activity of the downstream targets of IRS-1. 
In contrast to our SED western blot data; our EX western blot data was not as well 
defined. Our initial data (not included in this paper) had shown almost no differences in the 
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phosphorylation of Akt, GSK and dephosphorylation of GS between the basal and insulin-
stimulated exercise muscles. There are numerous studies reporting the maintenance and 
increased activity of the insulin signaling cascade with exercise157,158. However, we could not 
observe the anticipated increases in the phosphorylation of Akt, GSK and dephosphorylation of 
GS with insulin stimulation and other studies have reported a similar discrepancy159.  The reason 
for this discrepancy could be due to a negative feedback loop from increased glycogen in the EX 
muscle160. Increased glycogen content would inhibit stimulation of insulin signaling thus 
preventing phosphorylation of Akt, GSK and dephosphorylation of GS. Manabe et al. (2013) 
revealed that voluntary exercise training decreased the phosphorylation and deactivation of 
GSK-3α/β in muscle159.  Regardless of the reduction in GSK-3α/β phosphorylation GS activity 
was still increased in these trained muscles, which is probably due to the allosteric activation of 
GS through increased intramyocellular G6P concentrations in exercise muscles159. Considering 
the conclusions from previous work, the increased G6P content found in our results and the 
robust glycogen synthesis rates found in our basal and insulin stimulated exercise muscles we 
suggest the insulin signalling cascade in the EX condition was by-passed due to exercise training 
causing increased GS expression and allosteric activation of GS159. 
Chronic HF feeding severely reduces glycogen synthesis rates of all muscles, but exercise can 
protect HF fed muscles from blunted glycogen synthesis rates  
 
With regards to glycogen synthesis, we have shown previously that G6P content is 
greater in EX muscles than in SED muscles. This would likely cause allosteric activation of GS, 
leading to higher rates of basal glycogen synthesis rates in both EX SC and EX HF muscles. 
Additionally, this increase could be a result of the chronic exercise training causing an up-
regulation of the active form of GS which would lead to increases of basal glycogen synthesis 
rates159.  
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Underlining the protective effect of exercise from HF-induced insulin resistance, as the 
HF diet did not cause the EX HF group to exhibit lesser insulin stimulated glycogen synthesis 
rates than the EX SC condition. We also found that insulin-stimulated glycogen synthesis rates in 
Sol, EDL, and Epit muscles of SED HF rats were blunted. Considering the severely reduced 
activity of the key mechanistic enzymes in the insulin signaling cascade and the decreased G6P 
content already reported in SED HF rats, it was clear why glycogen synthesis rates were 
significantly lower than all other groups. Our work shows that muscles with greater oxidative 
capacity do not have a protective affect over diet induced insulin resistance. 
Is the Sol the most severely affected muscle? 
 
In fact based on our results, we hypothesized that perhaps the Sol (the muscle with the 
greatest oxidative capacity) was the most profoundly affected muscle with regards to insulin 
resistance. Our results indicate that the SED SC Sol provides significantly higher fold changes of 
insulin stimulated glycogen synthesis compared to all other conditions. However, in the SED HF 
condition Sol muscle produced fold changes that were significantly smaller than the SED SC and 
EX HF conditions. Highlighting the physiological toll that physical inactivity and the HF diet 
had on the Sol muscle. The highest fold changes in glycogen synthesis rates are found in the Sols 
because it contains the most insulin-sensitive type I fibers than the other muscles23. This is 
compatible with the fact that type 1 fibers display a greater degree of insulin binding and 
receptor kinase phosphorylation than type II fibers24. With these properties in mind, the 
disappearance of the Sol’s significant fold change in the HF condition was mostly likely due to 
the Sol’s more insulin sensitive properties succumbing to the deleterious effects of a lipid-rich 
diet.  
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Our concerns with respect to the Sol being the most affected muscle are supported by 
Gaster et al (2001) who found that GLUT4 density of type I fibers was significantly lower than 
type II fibers in T2D subjects161. If in fact the there is less GLUT4 in type I fibers of T2D 
subjects then this could provide a possible explanation for the disappearance of the glycogen 
synthesis fold changes in the Sol. Moreover, triglyceride content data (appendix) showed the 
highest concentrations of triglycerides were found in the Sol of SED HF rats. These results also 
suggest the Sol SED HF muscle could have been the most affected muscle. Research has found 
that triglycerides content more closely correlates with insulin resistance than BMI or total 
adiposity143. However, most researchers agree that the triglycerides themselves do not directly 
cause insulin resistance rather they act as surrogates for increased fatty acid metabolites which 
have a direct link to the pathogenesis of the insulin signaling cascade143,164.  
Furthermore, our finding of EX HF Sol muscle exhibiting significantly greater fold 
changes than the SED HF was a positive and yet peculiar finding, as exercise is clearly 
protecting the EX HF Sol from any harmful effects of the HF diet, possibly due to the increase 
mitochondria biogenesis that occurs in EX muscle along with exercise training stimulating a 
greater increase in GLUT 4 content in type I fibers146,151. As the Sol is the most insulin sensitive 
and contains the greatest amount of mitochondria between all the muscles then increasing the 
oxidative capacity through exercise would only serve to better the glycogen synthesis ability of 
this muscle. However, it was unusual that the EX SC Sol muscle did not exhibit similar if not 
greater fold changes to the EX HF Sol when we consider that exercise training should increase 
the GLUT 4 content of this type I fiber rich muscle.  
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Skeletal muscle insulin resistance is most likely a result of both the Randle cycle and an 
overwhelmed mitochondria 
 
Lastly, our study demonstrates that chronic HF-feeding increases oxidation rates. 
Interestingly, this finding falls in line with an argument against the involvement of mitochondria 
in skeletal muscle insulin resistance. In 2013 Dr. Holloszy proposed that mitochondrial 
deficiency has little influence on insulin resistance, for the following reasons: a) studies have 
shown that rodents who are fed a high fat diet display an increase in mitochondrial content while 
developing insulin resistance, b) mitochondrial deficiency severe enough to impair fat oxidation 
will lead to an increase in insulin action not an decrease and c) similar to the results in our study, 
studies have shown that insulin resistant subjects have higher fat oxidation rates than insulin 
sensitive subjects165. However, more recent work has supported the theory of mitochondria 
involved in skeletal muscle insulin resistance. A study by Henstridge et al. (2014) showed 
increasing heat shock protein 72 expression in mice causes increased oxidative capacity and 
mitochondrial number166. These mice are protected from HF-induced skeletal muscle insulin 
resistance166. This work clearly indicates the influence of mitochondria on the development of 
skeletal muscle insulin resistance. Thus, we believe that insulin resistance comes about in the 
SED HF muscles due to mitochondrial dysfunction. Although it is true, that as Dr. Holloszy 
proposes, HF-feeding increases mitochondrial activity and content, as our study demonstrates the 
highest rates of oxidation were present in SED HF muscles. These high rates were present due to 
the consumption of a HF diet providing FAs beyond the oxidation means of the myocyte, leading 
to the overwhelmed mitochondria in the muscle. Our findings are compatible with the theory 
purposed by Muoio et al (2006) who proposed a modified version of the Randle cycle whereby 
high fat feeding increased fatty acid oxidation rates, which leads to the acceleration of 
incomplete fatty acid oxidation143.  This acceleration, as seen in our palmitate oxidation results, 
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most likely resulted from a mismatch between the rates of β-oxidation and TCA cycle causing 
mitochondrial stress143. This stress is characterized by disruptions in the redox status and 
depletion of the CoA and carnitine levels143. With the depletion of CoA and carnitine the flow of 
fatty acid transport to the mitochondria is interrupted causing for incomplete oxidation143.  The 
incomplete oxidation would enrich the myocyte with toxic lipid metabolites, which would lead to 
lipid mediated insulin resistance.  
Our conclusion and Muoio’s theory is supported by the work of Keung et al. (2013) who 
reported that inhibiting CPT-1 in mice increased pyruvate dehydrogenase activity, increased 
membrane GLUT4 content, and insulin-stimulated Akt phosphorylation167. In addition, these 
mice’s intramyocellular DAG content was decreased167. Meaning that decreased fatty acid 
uptake and utilization lead to increased carbohydrate usage. Moreover, inhibition of CPT-1 in 
these mice caused increased insulin sensitivity. However, research that shows increasing fatty 
acid oxidation improves insulin signaling in muscle is at odds with our conclusion. Bruce et al. 
(2009) reported that increasing muscle CPT1 expression in HF fed rats allows for even more 
long chain fatty acids to enter the mitochondria and undergo more oxidation than under normal 
conditions168. This prevented the build up of harmful lipid intermediates which would otherwise 
affect the insulin signaling by increasing the amount of fatty acids that can enter the 
mitochondria168.  However, this could suggest that the amount CPT-1 content is the variable that 
can differentiate a HF-induced insulin resistant myocyte from an insulin sensitive myocyte. 
Suggesting that the mitochondria in the wild type rodent has the capacity to deal with abundance 
of lipids from a HF-diet but as it does not have enough CPT-1 to cope with the abundance of 
cytosolic fatty acids, this would then lead to the build up of toxic lipid intermediates.  
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Discussing the pathogenesis of high-fat induced skeletal muscle insulin resistance in a fiber type 
specific manner  
 
Finally, recent work has shown that knockout pyruvate dehydrogenase kinase 2 and 4 
mice (which leads to constitutively activated pyruvate dehydrogenase) are not protected from 
HF-induced insulin resistance169. The study indicated that genetically removing glucose 
oxidation inhibitors causes substrate usage to be shifted to glucose and although this shift 
increases glucose oxidation, it does not prevent a severe decrease in insulin-stimulated muscle 
glucose uptake169.  Furthermore, HF-feeding in this study led to decreases in fatty acid oxidation. 
These results conflict with our and other researchers views on the pathogenesis of insulin 
resistance and they highlight that the original Randle does retain some accuracy in describing 
insulin resistance and the interplay between glucose-fatty acid usage in a state of lipid 
oversupply. However, this study used the quadriceps, which is a muscle with mostly glycolytic 
fibers. As our study has shown muscles with type II fibers undergo less oxidation, thus the 
required increase in fatty acid oxidation, which produces citrate concentrations, which would 
inhibit PDH are less likely to occur in this fiber type. As oppose to the type I fibers, which are 
rich in mitochondria and can produce citrate concentrations that would inhibit PDH. In 
conclusion, it seems that a more thorough approach to the discussion of skeletal muscle insulin 
resistance is required. Findings need to be limited to specific muscle fiber type rather than 
studying muscles that contain different muscle fibers and extrapolating results to apply to all 
muscle fiber types. With this outlook we believe that type I and II fibers are both affected by 
DAG mediated insulin resistance. However, in the case of Type I fibers we believe they could be 
affected by the proposed modified Randle cycle, while it seems that type II fibers are affected by 
a build of toxic lipid intermediates as a result the lower oxidative capacity.  
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Conclusion 
However each muscle fiber type may be affected, it is clear that all SED HF muscles 
displayed blunted glycogen synthesis rates and insulin-signaling. In addition, these muscles also 
display low levels of G6P content and higher concentrations of circulating blood glucose and 
insulin. Indicating that our study was successful in showing that HF diet and lack of physical 
activity will lead to skeletal muscle insulin resistance in all muscle fiber types, while our work 
also showed that a higher oxidative capacity does not provide a protective effect from insulin 
resistance. Additionally, while most studies generalize their findings concerning skeletal muscle 
insulin resistance to all muscle fiber types, this study discusses skeletal muscle insulin resistance 
in a fiber type specific manner. Our work suggests that perhaps oxidative fibers are affected 
more severely by insulin resistance than glycolytic ones. The higher concentrations of 
triglycerides in Sol muscle and the disappearance of the significant glycogen synthesis fold 
change in the SED HF condition support our theory. Moreover, if our conclusion concerning the 
development of mitochondrial dysfunction is accurate, then it would stand to reason that the 
mitochondria rich type I fibers in the Sol would be more severely affected by this than the type II 
fibers found in the EDL and Epit. Lastly, if our work was to consider the other pathways in the 
pathogenesis of insulin resistance then it would stand to reason that the mitochondrial rich type I 
fibers would be more affected by the increases in ROS production.  
 However, our study does possess limitations in that it lacks evidence, which underlines 
the direct involvement of DAG. This was not presented due to attempts at measuring 
intramuscular DAG content being unsuccessful, thus in the next phase of our study we would 
like to continue our pursuit for the measurements of intracellular concentrations of DAG. 
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Finally, the importance of exercise as a major therapeutic tool in dealing with insulin 
resistance must be stated. In our work it is clear through the significantly increased glycogen 
synthesis rates, normal concentrations of circulating insulin, the appropriate regulation glycemia 
after glucose infusion and increased G6P content that chronic endurance exercise did seem to 
exert somewhat of a protective effect against high fat diet-induced insulin resistance in oxidative 
and glycolytic muscles. This protective effect of exercise is likely due to the shift of fiber type 
expression to more insulin sensitive type I fibers. The development of these characteristics would 
also explain why insulin resistance was prevented in the trained oxidative muscle, and why 
higher glycogen synthesis fold changes were observed in EX HF Sol muscle. 
6.2 Future Directions !
Previous work done in our lab has suggested that oxidative muscles develop insulin 
resistance as a result of substrate competition while insulin resistance in glycolytic muscles is 
due to accretion of lipid intermediates. We want to clarify that insulin resistance in all muscles is 
indeed a result of toxic lipid build up by measuring DAG content in all the muscles. We were 
previously extracting lipids from muscle homogenates then using DAG kinase we would label 
DAG molecules with radioactive P-32 creating phosphatidic acid, then isolating labeled 
phosphatidic molecules using TLC and finally superimposing the silica gel plate on a 
phosphorimaging screen to be quantified using densitometry. In the future, we would like to use 
mass spectrometry as it has been shown to be the most effective way of measuring DAG in 
muscle tissue171. In conjunction with the DAG assays, we would like conduct western blot 
analysis on SED HF muscles probing for the 307-serine residue of the IRS-1 protein172. We 
predict that higher levels of DAG content should correlate with more 307-serine residue 
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phosphorylation. These results will also help establish if DAG mediated insulin resistance is 
developed in type II fibers or if this fiber type is differently affected. 
Finally, to provide support to the Muoio hypothesis, we would like to test the remaining 
blood samples for acyl-carnitine esters. If in fact the mitochondria are dysfunctioning then excess 
acetyl-CoA and other acetyl-CoA intermediates are converted back into acyl-carnitine via CPT 
2143. The acyl-carnitine esters that are formed can exit the matrix of the mitochondria through 
carnitine acylcarnitine translocase, then once inside the cytoplasm, they can enter the blood 
stream143. Thus, there will be an increase in the concentrations of acyl-carnitine esters in the 
blood.   
 !!!!!!!!!!!!!!!!!!!!!!!!
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Appendix A: 
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Intramuscular triglyceride measurements of Sol, EDL and Epit muscle of SED SC (SC) and SED 
HF (HF) groups. Data are presented as mean ± SEM. Two-way ANOVA followed by a 
Bonferonni post-test. N=1-4. * p< 0.01 vs. EDL SC and EDL HF 
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Intramuscular glycogen content measurements of Sol (A), EDL (B) and Epit (C) muscle of SED 
SC, EX SC, SED HF and EX HF groups. Data are presented as mean ± SEM. Two-way ANOVA 
followed by a Bonferonni post-test. 
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7.0 Detailed experimental methods 
7.1 Glucose-6-phosphate assay kit 
 
In this assay, glucose-6-phosphate was oxidized which generated a product that is used to 
convert a colorless probe into a colored product with an absorbance of 450 nm. This kit can 
identify glucose-6-phosphate from 1 to 30 nmol, with a detection sensitivity of ~10uM. 
Store kit in -20 freezer, away from light. Warm the Glucose 6 Phosphate Assay Buffer to room 
temperature before use. Centrifuge all vials before use. 
Kit components: 
Glucose 6 Phosphate Assay Buffer   25ml 
Glucose 6 Phosphate Enzyme Mix  1 vial 
(lyophilized) 
Glucose 6 Phosphate Substrate Mix  1 vial 
(lyophilized) 
Glucose 6 Phosphate Standard  1 vial 
(10umol; lyophilized) 
 
GLUCOSE 6 PHOSPHATE STANDARD:  
Dissolve in 100 µl in dH20 producing 100 nmol/µl Glucose 6 Phosphate Standard solution. Keep 
on ice while in use. 
 
GLUCOSE 6 PHOSPHATE ENZYME MIX:  
Dissolve with 220 µL dH2O. Pipette up and down to dissolve. Aliquot and store at -20°C. Avoid 
repeated freeze/thaw cycles. Keep on ice while in use. Avoid repeated freeze/thaw cycles. Use 
within two months. 
 
GLUCOSE 6 PHOSPHATE SUBSTRATE MIX: Dissolve in 220 µL of Glucose 6 Phosphate 
Assay Buffer. Pipette up and down to dissolve. Keep on ice while in use. Stable for 2 months at 
+4°C. 
 
Addition items required: 
Clear bottom 96-well plate 
Colorimetric plate reader 
Centrifuge 
Orbital shaker 
Pipette and pipette tips 
 
1) Sample preparation: 
A) For muscle tissue, ~100mg was homogenized in ice cold PBS (ph 6.5-8.0). 
Homogenized tissue was then centrifuged at top speed for 10 minutes. 
B) Enzymes in samples may interfere with the assay; as a result samples were 
deproteinzed using a 10kDa molecular weight cut off spin column. 
C) Each sample was centrifuged for 1 hour at max speed whilst inside a 10kDa 
molecular weight cut spin column. 
2) Standard curve preparation: 
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Dilute Glucose 6 Phosphate Standard to 1nmol/µl by adding 10 µl of the 100-nmol/µl 
standard to 990ul of dH2O and mix well. Proceed to add 0, 2, 4, 6, 8 and 10 µl into a 
series of standards wells on the 96-well plate. Finally, adjust volume to 50 µl/well using 
the Glucose 6 Phosphate Assay Buffer to create 0, 2, 4, 6, 8 and 10 nmol/well of Glucose 
6 Phosphate standard. 
3) Reaction mix: 
Mix enough reaction mix for the number of samples and standards that have been 
prepared. Each well requires 50µl of reaction mix containing: 
Item Reaction Mix Background 
Assay Buffer 46 µl 48 µl 
Enzyme Mix 2 µl -- 
Substrate Mix 2 µl 2 µl 
 
Protect reaction mix from light and proceed to add 50 µl/well to each standard and 
sample well. Add 50 µl of background into allocated background wells. 
4) Incubate at room temperature for 30 minutes. Place plate on shaker while incubation 
occurs. 
5) Place plate in colorimetric plate reader and measure OD at 450 nm. 
 
 
7.1 Western Blotting Buffers  !
10x Running Buffer (pH- 8.3) 
144g  Glycine 
30.34g  Tris base 
10g  SDS 
Dissolve contents in 1L of ddH20 and store at room temperature. 
 
1x Running Buffer (pH- 8.3) 
10%  10x Running buffer 
90%  ddH20 
Mix solutions and store at room temperature. 
 
10x Transfer Buffer (pH- 8.3) 
144g   Glycine 
30.3g  Tris base 
Dissolve contents in 1L of ddH20  and store at room temperature. 
 
1x Transfer Buffer (pH- 8.3) 
70%  ddH20 
20%  Methanol 
10%  10x Transfer buffer 
Mix solutions and store at -20°C prior to use. 
 
10x Wash Buffer  
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60.57g  Tris base 
87.66g  Sodium Chloride (NaCl) 
Dissolve contents in 1L of ddH20, store at room temperature. 
 
1x Wash Buffer 
10%   10x Wash buffer 
90%  ddH20  
Add 500µl/L of Tween-20 and NP-40. 
Mix solutions and store at room temperature. 
 
Blocking Buffer 
3% BSA (w/v: 1.5g/50mL)  
Dissolve in 1x Wash buffer, store at 4°C. 
 
Antibody (Ab) Buffer 
1° Ab- 1part blocking buffer + 2 parts wash buffer + 0.02% NaAzide (stock in ddH20) 
2°Ab- 1part blocking buffer + 2 parts wash buffer (NO NaAzide).  
Typically 1:1000-1:5000 dilution is appropriate for an Ab, may vary depending on how good the 
signal is.  
 
Resolving gl Tris Buffer (1.5M) (pH-8.8) 
90.86g/500mL ddH20 
 
Stacking gel Tris Buffer (0.5M) (pH-6.8) 
30.3g/500mL ddH20 
 
10% APS Solution 
10% (w/v) Ammoniumperoxide Sulfate in ddH20. 
Use 0.1g/mL 
Store at -20°C.  
 
10% SDS Solution 
10% (w/v) Sodium dodecylsulfate in ddH20 
Use 1g/10mL 
Store at room temperature. 
 
Lysis Buffer for Protein Determination prior to Western blot 
 
Reagent Concentration/MW 
NaCl 135mmol/L (MW=58.44) 
MgCl2 1mmol/L (MW=203.3) 
KCl 2.7mmol/L (MW=74.55) 
Tris (pH 8) 20mmol/L (MW=121.14) 
Triton 1% ~500ul 
Glycerol 10% ~500ul 
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Prepare lysis buffer stock and store at -20°C. Aliquot desired volumes and add protease 
(complete ULTRA Tablets) and phosphatise (PhoStop) inhibitors just prior to use.  
 
Laemmli Sample Buffer (2x)- (Bio-Rad, Cat#161-0737) 
Per 1mL: 950µl of 2x Laemmli sample buffer 
  50µl β-Mercaptoethanol 
Store at room temperature. Dilute the sample (1 in 2) with sample buffer and boil for 5min.  
 
Preparation of tissue lysates: 
1. After extraction, tissues are snap frozen and stored at -80°C. 
2. Weigh tissues (~20mg skeletal muscle) and add to 250µl lysis buffer. 
3. Homogenize tissue. Keep on ice as much as possible to avoid heating up the sample. 
4. Centrifuge homogenate for 5min at 13,000rpm at 4°C.  
5. Remove middle aqueous protein-rich layer and place in a fresh microtube.  
6. Centrifuge extracted sample for 1min at 13,000rpm at 4°C and transfer to a fresh 
microtube. Discard any residual cell debris. 
7. Take an aliquot from each sample for protein determination by the Bradford method. 
8. Dilute sample with 2x Laemmli sample buffer (1:1 v/v), vortex well and boil samples for 
5min. 
9. Samples can be used immediately for western blots or stored at -80°C. 
7.3 Western Blotting Protocol !
Preparing the Gel/Gel Recipes 
 
Note: Use low % acrylamide gel when probing for large proteins, and a higher % acrylamide gel 
for smaller proteins.  
 
Resolving Gel  
RESOLVING GEL  2 gels (10%) 
ddH20 8.2 mL 
30% Acrylamide (37:5:1) 6.6 mL 
Tris-HCL (1.5M, pH 6.8) 5 mL 
10% SDS 0.2 mL 
Temed 20 µL 
10% APS 100 µL 
Add APS and Temed immediately prior to pouring the gel into plates. Pipette a thin layer of 
Isopropanol over the top of the gel to prevent resolving gel from drying out. Allow gel to set 
(approx. 20min).  
 
Stacking Gel  
STACKING GEL (4%) 2 gels (10mL) 
ddH20 6.1 mL 
30% Acrylamide (37:5:1) 1.3 mL 
Tris-HCL (0.5M, pH 6.8) 2.5 mL 
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10% SDS 0.1 mL 
Temed 10 µL 
10% APS 50 µL 
Once the resolving gel is set, pour out Isopropanol and carefully blot excess with filter paper. 
Pour stacking gel on top of resolving gel. Put combs in place. Allow gel to set (approx. 20min).  
 
 
Running the Gel 
1. Take samples out of -80° freezer and place on ice. 
2. Place gels into tanks, and add 1x running buffer to fill the tank. 
3. Once samples have thawed, spin in centrifuge until max speed is reached.  
4. Take out combs and pipette 6µL Bio-Rad protein ladder.  
5. Add samples into each well accordingly. 
6. Top up running buffer to make sure tank is full. 
7. Match black electrodes to black and red to red. 
8. Turn on the voltage for 60V for 30min, after, turn it up to 120V for approx. 1.5hours until 
dye runs off the gel. 
9. At this point, you can prepare 1x transfer buffer. Once transfer buffer is well mixed, 
cover with parafilm and place in the -20°C freezer until ready for transfer. 
 
Transferring the Gel onto a membrane 
1. Fill a dish with cold transfer buffer. 
2. Cut out equal sized membranes and place in methanol for 2 minutes to activate. Also cut 
out equal sized filter papers and prepare the appropriate number of foam pads. 
3. Place membranes in transfer buffer after activation. 
4. Once dye has run off the gel, remove the gels from tank and soak in transfer buffer. 
Carefully remove glass plates. Cut off and discard combs of the gel. Loosen gel from the 
glass plate with scraper. Allow for the gel to sit in transfer buffer. 
5. In a dish, place the black side of the cassette on the bottom, and place two foam pads and 
2 filter papers on top. Ensure there are no bubbles. 
6. Carefully place gel on top of filter paper and use the roller to get any air bubbles out. 
Make sure gel is in the correct orientation so that the ladder will end up on the left side of 
the membrane when removed.  
Note: transfer runs from negative (black) to positive (red). Always ensure proteins will 
run from gel to the membrane.  
7. Place membrane on top of the gel and roll out any bubbles. 
8. Place 2 more filter papers on top and roll out any bubbles.  
9. Add one more foam pad and roll out any bubbles.  
10. Carefully close sandwich and place into transfer tank. Make sure black matches black and 
red matches red. Repeat as necessary for the number of gels used. 
11. Place ice pack in tank to keep buffer cold. Attach lid by matching electrodes- black-to-
black, and red-to-red. Surround transfer tank with ice to keep cold.  
12. Turn on transfer at 120V for 2.5 hours or at 60V overnight.  
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13. Check on temperature throughout transfer time to ensure no overheating.   
 
Probing the membrane 
1. Prepare containers to hold blocking buffer for each membrane, approx. 10mL per 
container. 
2. Once transfer has finished, open cassettes and quickly place membranes in containers 
with blocking buffer. 
3. Allow the membranes to rinse in the blocking buffer for 1hr at room temperature. 
4. Pour out blocking buffer and add primary antibody (1°Ab).  
5. Incubate overnight at 4°C. Ensure containers are fully sealed to avoid evaporation. 
6. The next day, remove 1°Ab and wash membranes 5x for 10min each with 10mL 1x wash 
buffer to rid the membrane of any unbound Ab. 
7. Add secondary antibody (2° Ab) and allow membranes to rinse for 1hr at room 
temperature.  
8. Remove 2°Ab and wash membranes 5x for 10min each with 10mL 1x wash buffer to rid 
the membrane of any unbound 2°Ab. 
9. Membranes are ready for developing 
 
Developing the membrane 
1. For each membrane, use 2mL chemiluminescence (Millipore Immobilon Western 
Chemiluminescent HRP substrate) per membrane and incubate for 2 minutes.  
2. Dip membranes into ddH20 to rinse and place on transparency inside cassette.  
3. In the darkroom, expose film for desired time. 
4. Place film in developer for a few seconds until signal appears. Dip into water and to stop 
the reaction, place in fixer solution. Ensure ample fixing time.  
5. Rinse with water and allow to dry.   
 
7.4 Complexation of Palmitic Acid !
1. Prepare 30mL of KRB Buffer (without glucose) 
2. Add 3.75g FA-free BSA (Sigma Cat# A3803) to get a 12.5% solution 
3. Heat to 50°C in water bath 
4. Take 1600mg palmitic acid (Sigma Cat# P-5585) to put into a 2mL eppendorf 
5. Dissolve palmitic acid with 100µl NaOH (10N) and vortex vigorously 
6. Add palmitic acid into preheated medium while stirring. (note; it will precipitate) 
7. Pour into falcon tube, protected from light 
8. Incubate in 50°C water bath for 4+ hours while shaking at 150-200rpm 
9. After the incubation period, filter solution to get chunks out using a 10mL syringe and 
sterile strainer 
10. pH to 7.4 
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11. Aliquot solution and store at -20°C 
 
7.5 Palmitate Oxidation Protocol (Incorporation of [1-14C] Palmitic acid into 14CO2)  !
1. Following extraction, weigh tissues (~20mg muscle) and place into scintillation vial 
containing 2mls of KRBS Ringer buffer. 
2. Gasify each vial for 1 hour and incubate at 37°C 
3. After 1 hour, add 200µl (1:1, vol/vol) 2-phenylethylamine/methanol onto loosely folded 
filter paper placed inside a 1.5ml eppendorf. 
4. Gasify each scintillation vial for approx 1 hour, and incubate for 1 hour at 37°C 
5. After 1 hour, add 200µl of H2SO4 (5N) to acidify media. Incubate for 1 hour at 37°C 
6. Collect filter papers and transfer to corresponding scintillation vial containing 10mL of 
ECOLITE+ liquid scintillation cocktail (MP Biomedicals Cat #01882475) and place in 
scintillation counter for radioactivity counting 
 
 
7.6 Glycogen Synthesis Protocol (Incorporation of D-[14C] glucose into Glycogen) !
1. Transport the muscle slice (weighing ~ 20mg) to a 1.5ml eppendorf and add 500µl of 1M 
KOH. 
2. Incubate the sample on the heat block for 30min @ 80-90°C. 
3. 15min into the incubation period gently shake the eppendorf around once to ensure 
complete digestion. 
4. Extract 400µl for glycogen content and place in a 2ml eppendorf. 
5. Add 100µl of carrier glycogen to each sample. 
6. Add 80µl of saturated Na2SO4 to each sample 
7. Add 1.2ml of cold ethanol 
8. Gently vortex each sample and incubate at -20°C overnight to allow precipitation. 
9. On the following day, check for precipitation and centrifuge the samples for 
20min @ 3000rpm. 
10. Discard the resultant supernatant. 
11. Dissolve the pellet in 500µl of ddH20. 
12. Extract 400µl of sample and add to 5ml of scintillation fluid (ECOLITE+ liquid 
scintillation cocktail (MP Biomedicals Cat #01882475)) for counting. 
 
Glycogen Synthesis Reagents 
 
Note: Adjust volumes accordingly depending on number of samples. 
 
1N KOH (pH off the scale) 
5.61g KOH 
Complete to 100ml using ddH2O 
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Saturated Na2SO4 
Dissolve powdered Na2SO4 in ddH2O until precipitation forms. Precipitate formation is a sign of 
saturation. 
 
Cold Ethanol 
Place 100% Ethanol in a 50ml falcon tube and leave in -20°C freezer. 
 
7.7 Measuring Triglyceride Content using commercially available calorimetric Kit !
Note: This procedure can be done over one or two days. 
Materials 
• Triglyceride Quantification Kit (100 samples including 6 standards) 
(Cat# ab65336) 
• 5ml Tubes (1 tube/sample) 
• 5% NP40 
• ddH2O 
 
Day 1 – Sample Preparation 
1. Determine the number of samples to be assayed and make an appropriate amount of 5% NP40 
(diluted in water) (1ml/sample). 
2. Add 100mg of tissue (muscle) to 1ml of 5% NP40 in a 5ml tube. 
3. Heat the sample in the water bath for 10min @ 90°C. 
4. Homogenize the sample in the 5ml tubes. 
5. Heat the homogenized sample for 5min @ 90°C. 
6. Remove the tubes from the water bath and let them cool down to room temperature. 
7. Heat the sample once again for 5min @ 90°C. 
8. Centrifuge the samples for 2 min at max speed. 
9. Extract 20 µl for measuring protein content and store in an eppendorf. 
10. Extract the remaining sample from the 5ml tubes and dispense into a separate eppendorf. (Be 
sure not to extract any insoluble material) 
11. Store the samples at -80°C or continue procedure. 
 
Day 2 – Prepare Standard Curve and Run Samples. 
Note: Make room for 1 blank/condition. 
1. Allow samples to thaw. 
2. Vortex the samples and centrifuge them @13,200rpm for 10min. 
3. While vortexing, reconstitute the enzyme mix in 220µl of assay buffer. Also, reconstitute the 
lipase in 220µl of assay buffer. Make aliquots and store unused portion in -20°C. 
4. Dilute the stock standard (1mM) to 0.2mM by adding 100µl of the stock to 400µl of assay 
buffer provided in the kit. 
5. Take a 96-well plate and start putting in the standards. Add 0µl, 10µl, 20µl, 30µl, 40 µl, and 50 
µl of the 0.2mM standard in series. 
6. Use assay buffer to top up all standards to a final volume of 50µl. 
7. Dilute each of sample 10x by adding 10µl of sample to 90µl of ddH2O. Mix well. 
8. For muscle put 50 µl of the diluted sample per well.  
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9. Add 2ul of lipase to every well INCLUDING the standards. For blanks (1 blank/condition) 
add 2µl of assay buffer instead of the lipase. (This is the only difference between blanks and 
samples) 
10. Let the well incubate for 20 min (Gently shake for 2min. Use the remaining 18min to make 
reaction mix). 
11. Reaction mix (Light sensitive. Wrap in foil immediately. Store at room temperature) 
12. Add 50µl of reaction mix to ALL wells including standards and blanks. 
13. Shake the plate for 2min and incubate in a light-protected area for 1h. 
14. Use the plate reader to read at 570nm. 
15. Subtract your blanks from your samples. 
16. Subtract absorbance of blank (standard 0) from all standards and samples. 
17. Calculate concentration. 
 
7.8 Measuring Circulating Insulin by ELISA !
1. Fast the animals for 14-hr then obtain a blood sample from the saphenous vein. 
2. Always keep blood on ice. 
3. Centrifuge the blood at for 10min @ 13,000rpm (4°C) 
4. Extract the plasma (supernatant) and place into another labeled eppendorf. 
Store at -80°C until you are ready to run the ELISA. 
5. When ready to assay, pre-warm all reagents of the EMD Millipore ELISA kit (Cat. # EZRMI-
13K) to room temperature. 
6. Dilute the provided 10X wash buffer by 10-fold. 
7. Determine the number of samples to be assayed and place any extra microtiter strips in 2-8°C. 
8. Place the microtiter strips that you will be using in a plate holder and wash 3 times with 300µl 
of diluted wash buffer. 
9. Remove buffer from wells by tapping lightly onto an absorbent surface DO NOT let the wells 
dry completely. 
10. Add 10µl of assay buffer to each blank & sample wells. 
11. Add 10µl of Matrix solution to blank, standard, and control wells. 
12. Add 10µl of 0.2, 0.5, 1, 2, 5 and 10 ng/mL insulin standards in ascending order. 
13. Add 10µl of quality control 1 & 2 into their own wells. 
14. Add 10µl of sample into the remaining wells. 
15. Add 80ul of detection antibody to all wells 
16. Seal the plate and incubate at room temperature for 2h on an orbital shaker 
17. Remove plate sealer and tap onto an absorbent surface to empty contents. 
18. Wash the plate 3 times with 300µl of wash buffer by decanting after each wash. 
19. Add 100 µl of enzyme solution to each well. Seal with plate sealer and incubate for 30min at 
moderate speed on an orbital shaker. 
20. Remove the seal and decant the contents. 
21. Wash 6 times using diluted wash buffer making sure to decant contents after each wash. 
22. Add 100 µl of substrate solution to each well. Cover with plate sealer and shake for 20 min 
on orbital shaker. 
23. Add 100µl of stop solution to each well and mix well by hand. Ensure there are no bubbles 
and read using a plate reader at 450 and 590nm. Record absorbance. 
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24. Calculate insulin concentrations as outlined in the manual. 
7.9 Buffers for muscle slice incubation 
 
Stock solutions for Krebs Ringer Bicarbonate (KRB) Buffer 
Note: All solutions are made with ddH2O 
 
Quantity Reagent/Molarity 
0.9g in 100ml 0.154M NaCl (mw = 58.44) 
575mg in 50ml 0.154M KCl (mw = 74.55 
610mg in 50ml 0.11 CaCl2 (mw = 110.99) 
1.055g in 50ml 0.154M KH2PO4 (mw = 136.09) 
927mg in 50ml 0.154M MgSO4 (mw = 120.30) 
650mg in 50ml 0.154M NaHCO3 (mw = 84.01) 
*Gasify NaHCO3 with carbogen (95% O2/5% CO2) for 1h after assembly. Stock 
solutions can be stored at 0-4°C. 
 
KRB Buffer Assembly (for 100ml) 
Note: Adjust volumes accordingly depending on number of samples. 
For 100ml of KRB buffer: 
 
Quantity Reagent/Molarity 
78.6ml 0.154M NaCl 
3.08ml 0.154M KCl 
2.32ml 0.11 CaCl2 
0.768ml 0.154M KH2PO4 
0.768ml 0.154M MgSO4 
16.1ml 0.154M NaHCO3 
100mg 5.5mM Glucose 
715mg 30mM Hepes 
 
 
Once assembled, the KRB solution is gasified for 45min with carbogen (95% O2/5% CO2). pH 
the gasified KRB buffer to 7.4 using 10N NaOH. Finally add fatty acid free BSA (Sigma Cat# 
A3803) to the solution at a concentration of 4% (40mg/ml). 
 
For glycogen synthesis and glycogen content assays, take the required amount of KRB Buffer 
and add radiolabelled D-[14C] glucose at a concentration of 0.2 µCi/ml. 
 
 
 
 
 
 
 !
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Appendix B: 
Statement of Labor 
 
All experiments conducted in this study were carried out by Arta Mohasses (AM), Diane 
Sepa-Kishi (DSK), Michelle Victoria Wu (MVW), George Bikopolous (GB) and Abinas 
Uthayakumar (AU). AM, DSK, MVW and AU were involved in the training of animals, 
collection of food intake and body weight data, extraction of tissues and IPGTT. AM was 
responsible for measuring palmitate oxidation, triglyceride content, glycogen synthesis, insulin 
concentrations, glycogen content and G6P content with the help of AU. George Bikopolous 
carried out the western blots for this study. 
Dr. Rolando Ceddia is the primary investigator and supervisor of this project and this 
research was funded by the Natural Sciences and Engineering Research Council of Canada 
(NSERC) grant 311818-2011. 
 
 
